EP3221307B1 - Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof - Google Patents

Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof Download PDF

Info

Publication number
EP3221307B1
EP3221307B1 EP15820891.8A EP15820891A EP3221307B1 EP 3221307 B1 EP3221307 B1 EP 3221307B1 EP 15820891 A EP15820891 A EP 15820891A EP 3221307 B1 EP3221307 B1 EP 3221307B1
Authority
EP
European Patent Office
Prior art keywords
compound
triazin
piperidin
morpholino
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15820891.8A
Other languages
German (de)
French (fr)
Other versions
EP3221307A1 (en
Inventor
Thanusha THATIKONDA
Suresh Kumar
Umed SINGH
Priya MAHAJAN
Girish Mahajan
Amit NARGOTRA
Fayaz Malik
Dilip Manikrao Mondhe
Ram Asrey Vishwakarma
Parvinder Pal SINGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Publication of EP3221307A1 publication Critical patent/EP3221307A1/en
Application granted granted Critical
Publication of EP3221307B1 publication Critical patent/EP3221307B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens

Definitions

  • the class I PI3Ks are the most extensively studied among lipid kinases, are heterodimeric proteins; each containing a smaller regulatory domain and a larger 110 kDa catalytic domain, which occur in four isoforms differentiated as p110 ⁇ , p110 ⁇ , p110 ⁇ , and p110 ⁇ ( Walker et al., Mol. Cell 2000, 6, 909 ). Moreover, Isoform selective inhibitors capable of attenuating PI3K signalling should have significant therapeutic potential for the treatment of cancer, inflammatory ( Barber et al., Nat. Med. 2005, 11, 933 ), cardiovascular diseases and autoimmune disorders.
  • PI3K isoform inhibitors In the last decade, many small molecules have been discovered as PI3K isoform inhibitors and presenting the new opportunities as therapeutic agents. Some of the small molecules are presently in either phase I or II clinical trial against different type of cancers. Examples includes NVP-BEZ235 developed by Novartis, ( Garcia-Echeverria et al., WO2006/ 122806A2 ), NVP-BGT226 developed by Novartis, ( Kwang et al., Clin cancer res. 2011, 17(22), 7114 ), XL-147, XL-765 developed by Exelixis, ( P. Wu et al., Eur. J. Med. Chem.
  • the main object of the present invention is to provide 1,3,5-substituted triazine containing heterocyclic compounds as anti-cancer agents. Still another object of the present invention is to provide a process for the preparation of novel 1,3,5 -substituted based compounds. Yet another object of the present invention is to provide the 1,3,5-substituted triazine containing heterocyclic compounds for use in the treatment of cancer
  • the present invention relates to 1,3,5-substituted triazine containing heterocyclic compounds, their method of preparation and their use as drugs for treating cancer.
  • substituent 'S 1 ' is selected from one of the formula Ia or Ib and substituent 'S 2 ' selected from the group consisting of 1c 'X' is independently selected from any of NR 3 , O, CH 2 , 'R 1 , R 2 ' are independently selected from any of un/substituted alkyl C 1 -C 14 , un/substituted acyl C 2 to C 14 , un/substituted phenyl ring and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR 4 R 5 , CF 3 , CHCF 2 , CH 2 F, OCF 3 , OCH 2 CF 3 , OR 6 , NO 2 , NO, CHR 7 R 8 , alky
  • a preferred subclass have following formulas 1A or 1B belong to general formula 1 'X' is independently selected from any of NR 3 , O, CH 2 , 'R 1 , R 2 ,' are independently selected from any of following atom or groups un/substituted alkyl C 1 -C 14 , un/substituted acyl C 2 to C 14 , un/substituted phenyl ring, un/substituted heterocycles and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR 4 R 5 , CF 3 , CHCF 2 , CH 2 F, OCF 3 , OCH 2 CF 3 , OR 6 , NO 2 , NO, CHR 7 R 8 , alkyl chain from C 1 to C 14 , COOR 9 , CHO, COR 10 , COCF 3 , COCH 2 CF 3 , SR 11 , SOR 12 , SO 2 R 13 , SONR
  • a process for the preparation of the compounds of general formula 1 comprises the following steps:
  • a preferred subclass have following formulas 1A or 1B belong to general formula 1 'X' is independently selected from any of NR 3 , O, CH 2 , 'R 1 , R 2 ' are independently selected from any of following atom or groups un/substituted alkyl C 1 -C 14 , un/substituted acyl C 2 to C 14 , un/substituted phenyl ring, un/substituted heterocycles and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR 4 R 5 , CF 3 , CHCF 2 , CH 2 F, OCF 3 , OCH 2 CF 3 , OR 6 , NO 2 , NO, CHR 7 R 8 , alkyl chain from C 1 to C 14 , COOR 9 , CHO, COR 10 , COCF 3 COCH 2 CF 3 , SR 11 , SOR 12 , SO 2 R 13 , SONR 14 R 15
  • the compound of general formula 1 is useful as anti-cancer agent.
  • the compounds of formula 1A and 1B of general formula 1 inhibit PI3K ⁇ isoform.
  • the compounds of formula 1A and 1B of general formula 1 exhibit an in vitro cancer cell line activity.
  • Suitable acids for the preparation of the pharmaceutically acceptable salts are not limited to hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salyilic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid and methanesulfonic acid, boric acid, galactaric acid, gentisic acid, glucoheptonoic acid, D-gluconic acid, D-glucuronic acid, glycolic acid, hyppuric acid.
  • the present invention relates to the most highly preferred of the compounds of formula 1A and 1B, comprising of:
  • Cynuric chloride (1) (10g, 54.2 mmol, 1.0 eq) was substituted by morpholine (7) (4.72 ml, 5.42 mmol, 1.0 eq) in methylene chloride (60 ml), at -50 °C for 20 min to obtain intermediate (3).
  • the intermediate (3) (5 g, 1.0 eq) on further treatment with di-substitued amine (4) (1.4 eq) in presence of K 2 CO 3 (1.44 eq) in DMF (20 ml) , at -5 °C for 30 min and then at room temperature for 4 h led to intermediate (5) .
  • Cynuric chloride (1) (10g, 54.2 mmol, 1.0 eq) was substituted by morpholine (7) (4.72 ml, 5.42 mmol, 1.0 eq) in methylene chloride (60 ml), at -50 °C for 20 min to obtain intermediate (3).
  • the intermediate (3) (5 g, 1.0 eq) on further treatment with substitued indole (13) (1.4 eq) in presence of K 2 CO 3 (1.44 eq) in DMF (20 ml) , at -5 °C for 30 min and further stirring at room temperature for 4 h led to intermediate (14) .
  • Part B Biological Evaluation
  • PI3K alpha % of inhibition values of a drug measures the effectiveness of a compound in inhibiting biological or biochemical function.
  • the determination of enzyme based % of inhibition values helps in early analysis and estimation of the drug activities in order to narrow down drug candidates for further experimental purpose.
  • Human breast cancer cell lines MDAMB231, MFC-7 and human prostate carcinoma cell line PC-3 were obtained from European Collection of Cell Cultures (ECACC).
  • Cells were grown in RPMI-1440 medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/ml), streptomycin (100 ⁇ g/ml), L-glutamine (0.3 mg/ml), sodium pyruvate (550 mg/ml), and NaHCO 3 (2mg/ml).
  • FBS fetal bovine serum
  • penicillin 100 units/ml
  • streptomycin 100 ⁇ g/ml
  • L-glutamine 0.3 mg/ml
  • sodium pyruvate 550 mg/ml
  • NaHCO 3 2mg/ml
  • MTT assay was done to determine the viability of the cells and was done as described previously (Kumar etal, 2013). Briefly, 6 ⁇ 10 3 were seeded in 96 well plates and were treated with different concentrations of different molecules for 5 days. 20 ⁇ l of MTT dye (2.5mg/ml) was added 3 h before the termination of the experiment. Formazen crystals were dissolved in 150 ⁇ l of DMSO and OD was measured at 570 nm.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

    FIELD OF THE INVENTION
  • The present invention relates to novel 1,3,5-substituted triazine containing heterocyclic compounds of general formula 1, which inhibits phosphoinositide 3-kinase (PI3K). The invention also relates to their method of preparation and their use as an agents or drugs for cancer therapy.
    • BACKGROUND AND PRIOR ART OF THE INVENTION
  • At cellular level, phosphoinositide-3-kinase (PI3K) signalling contributes to many important processes, such as cell cycle progression, cell growth, survival and migration and intracellular vesicular transport. The PI3K represents the family of lipid kinases that can be classified into three subfamilies according to structure and substrate specificity viz., class I, class II and class III (Liu et al., Nature review drug discovery, 2009, 8, 627; Courteny et al., J Clin Oncol, 2010, 28, 1075). The class I PI3Ks are the most extensively studied among lipid kinases, are heterodimeric proteins; each containing a smaller regulatory domain and a larger 110 kDa catalytic domain, which occur in four isoforms differentiated as p110α, p110β, p110γ, and p110δ (Walker et al., Mol. Cell 2000, 6, 909). Moreover, Isoform selective inhibitors capable of attenuating PI3K signalling should have significant therapeutic potential for the treatment of cancer, inflammatory (Barber et al., Nat. Med. 2005, 11, 933), cardiovascular diseases and autoimmune disorders. In cancer, evidence suggests that inhibition of the class 1A PI3 kinase p110α appear to be the most appropriate to target, as in number of cancer, p110α isoform is amplified and activated (Stephens et al., Curr. Opin. Pharmacol. 2005, 5, 357).
  • In the last decade, many small molecules have been discovered as PI3K isoform inhibitors and presenting the new opportunities as therapeutic agents. Some of the small molecules are presently in either phase I or II clinical trial against different type of cancers. Examples includes NVP-BEZ235 developed by Novartis, ( Garcia-Echeverria et al., WO2006/ 122806A2 ), NVP-BGT226 developed by Novartis, (Kwang et al., Clin cancer res. 2011, 17(22), 7114), XL-147, XL-765 developed by Exelixis, (P. Wu et al., Eur. J. Med. Chem. 2011, 46, 5540), GDC0941 developed by Genentech, (Adrian et al., J. Med. Chem. 2008, 51, 5522), PKI-587 developed by Pfizer, (Mallon et al., Clin cancer res. 2011, 17(10), 3194), GSK1059615 developed by GSK, (Steven D. Knight et al., ACS Med. Chem. Lett. 2010, 1, 39), ZSTK474 developed by Zenyaku kogyo, (Yaguchi et al., J. Natl. Cancer inst. 2006, 98, 545; Kong et al., Cancer sci. 2007, 98, 1439; Gordon et al., J. Med. Chem. 2011, 54, 7105-7126; Gordon et al., WO2010/ 110686A1 ; Vladimir et al., WO2011/ 135520A1 ; Gordon et al., WO2010/ 110685A2 ; Venkatesan et al., WO2009/ 143317A1 ) etc. In spite of having many PI3K inhibitors in pre-clinical and different clinical trials, still there is need for the discovery of new PI3K inhibitors for the treatment of cancer.
    • OBJECTIVE OF THE INVENTION
  • The main object of the present invention is to provide 1,3,5-substituted triazine containing heterocyclic compounds as anti-cancer agents. Still another object of the present invention is to provide a process for the preparation of novel 1,3,5 -substituted based compounds. Yet another object of the present invention is to provide the 1,3,5-substituted triazine containing heterocyclic compounds for use in the treatment of cancer
    • SUMMARY OF THE INVENTION
  • The present invention relates to 1,3,5-substituted triazine containing heterocyclic compounds, their method of preparation and their use as drugs for treating cancer.
    Figure imgb0001
     Disclosed are compounds having a general formula 1:
    Wherein substituent 'S1' is selected from one of the formula Ia or Ib
    Figure imgb0002
     and substituent 'S2' selected from the group consisting of 1c
    Figure imgb0003
     'X' is independently selected from any of NR3, O, CH2,
    'R1, R2' are independently selected from any of un/substituted alkyl C1-C14, un/substituted acyl C2 to C14, un/substituted phenyl ring and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl etc either mono or di or poly at any of the available position
    R3 is independently selected from any of H, un/substituted alkyl C1-C14, un/substituted acyl C2 to C14, un/substituted phenyl ring and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl etc either mono or di or poly at any of the available position
    Figure imgb0004
     is independently selected from any of following un/substituted N-heterocyles such as indolyl, triazolyl, pyrrolyl, imidazoyl, benzotriazolyl, benzoimidazolyl, thiazoyl etc attached though N-atom or any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl
    'Ar' is independently selected from any of un/substituted phenyl, un/ substituted napthyl and attached through any of the available ring position and further substitution selected from any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl
    'Hetero-Ar' is independently selected from any of un/substituted hetrocycles such as pyridyl, triazolyl, triazinyl, pyrimidinyl, pyridazinyl, oxazolyl, furanyl, benzofuranyl, thiophenyl, pyrrolyl, imidazoyl, thiazoyl, quinolinyl, isoquinolinyl, benzooxazolyl, and benzothiazolyl, indolyl, benzotriazolyl, benzoimidazolyl etc and attached through any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl
    R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R14 and R17' are independently selected from any of following substitution such as H, linear alkyl chain C1 -C10, branched alkyl chain C3-C10, un/substituted phenyl ring.
  • A preferred subclass have following formulas 1A or 1B belong to general formula 1
    Figure imgb0005
     'X' is independently selected from any of NR3, O, CH2,
    'R1, R2,' are independently selected from any of following atom or groups un/substituted alkyl C1-C14, un/substituted acyl C2 to C14, un/substituted phenyl ring, un/substituted heterocycles and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl etc either mono or di or poly substituted at any of the available position
    R3 is independently selected from any of H, un/substituted alkyl C1-C14, un/substituted acyl C2 to C14, un/substituted phenyl ring and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl either mono or di or poly at any of the available position
    Figure imgb0006
     is independently selected from any of following un/substituted N-heterocyles such as indolyl, triazolyl, pyrrolyl, imidazoyl, benzotriazolyl, benzoimidazolyl, thiazoyl etc attached though N-atom or any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl,
    'Ar' is independently selected from any of un/substituted phenyl, un/ substituted napthyl etc and attached through any of the available ring position and further substitution selected from any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl,
    'Hetero-Ar' is independently selected from any of un/substituted hetrocycles such as pyridyl, triazolyl, triazinyl, pyrimidinyl, pyridazinyl, oxazolyl, furanyl, benzofuranyl, thiophenyl, pyrrolyl, imidazoyl, thiazoyl, quinolinyl, isoquinolinyl, benzooxazolyl, and benzothiazolyl, indolyl, benzotriazolyl, benzoimidazolyl etc and attached through any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl,
    R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R14 and R17' are independently selected from any of following substitution such as H, linear alkyl chain C1 -C10, branched alkyl chain C3-C10, un/substituted phenyl ring. The compounds of general formula 1 are useful as PI3K anti-cancer agent.
  • The compounds of general formula 1 inhibit PI3Kα isoform.
  • The compounds of general formula 1 exhibit an in vitro cancer cell line activity.
  • A process for the preparation of the compounds of general formula 1 comprises the following steps:
    1. (i) reacting disubstituted triazine compound of formula 5 or 8 with aryloxy piperidines or piperidones in an organic solvent selected from a group consisting of DMF, THF, CH3CN (added) in the presence of alkali metal carbonate selected from a group consisting of K2CO3, Na2CO3, Cs2CO3(added) at a temperature ranging between 10 °C to 80 °C for a period ranging between 1 to 24 hrs, to obtain compound of formula 1A(1-20) or 1B(1-20) or trisubstituted triazine compound 10 or 15,
    2. (ii) reacting trisubstituted triazine compound 10 or 15 with substituted aryl amine of formula 11, wherein FG4 is selected from a group consisting of 4F, 4-CF3, 4-OCH3, 4-Br, 3, 4 DiCl, 2-F, 2-OCH3, 2-CF3, 3-OCH3, 2-CH3, 4-CH3(added) in an organic solvent selected from a group consisting of DCM, DCE, THF, MeOH (added) in presence of acetic acid and a reducing agent selected from a group consisting of sodium triacetoxy borohydride, sodium borohydride (added) at a temperature ranging between 10 °C to 80 °C for a period renging between 1 to 24 hrs, to obtain compound 1B (21-40) or 1B (46-50) respectively,
    3. (iii) reacting trisubstituted triazine compound 1B21 with substituted aryl boronic acid of formula 12, wherein FG5 is selected from a group consisting of halogen or CF3, in an organic solvent selected from a group consisting of DCM, DCE, MeOH, CH3CN (added) in presence of triethylamine and copper acetate at a temperature ranging between 10 °C to 80 °C for a period in the range of 1 to 24 hrs, to obtain compound of formula 1B(41-45).
    BRIEF DESCRIPTION OF THE DRAWINGS
    • Fig 1 shows the synthetic approach (schemel) for the synthesis of compounds 1A (1-20).
    • Fig 2 shows the synthetic approach (scheme2) for the synthesis of compounds 1B (1-20).
    • Fig 3 shows the synthetic approach (scheme3) for the synthesis of compounds 1B (20-40).
    • Fig 4 shows the synthetic approach (scheme4) for the synthesis of compounds 1B (41-45).
    • Fig 5 shows the synthetic approach (scheme5) for the synthesis of compounds 1B (45-50).
      • Table 1 shows the structures of representative compounds IA (1-10) belong to formula IA and synthesized as per scheme 1 provided in (Fig 1).
      • Table 2 shows the structures of representative compounds IA (10-20) belong to formula IA and synthesized as per scheme 1 provided in (Fig 1).
      • Table 3 shows the structures of representative compounds IB (1-10) belong to formula IB and synthesized as per scheme 2 provided in (Fig 2).
      • Table 4 shows the structures of representative compounds IB (10-20) belong to formula IB and synthesized as per scheme 2 provided in (Fig 2).
      • Table 5 shows the structures of representative compounds IB (21-30) belong to formula IB and synthesized as per scheme 3 provided in (Fig 3).
      • Table 6 shows the structures of representative compounds IB (31-40) belong to formula IB and synthesized as per scheme 3 provided in (Fig 3).
      • Table 7 shows the structures of representative compounds IB (40-50) belong to formula IB and synthesized as per scheme 4 and scheme 5 provided in (Fig 4 & Fig 5).
      • Table 8 shows the inhibition results of compounds general formula 1 by enzyme based assay PI3Kα. *In vitro PI3K alpha kinase inhibition at 500nm; + indicates greater than 50% to 70% of inhibition and ++ indicates greater than 70% of inhibition.
      • Table 9 shows the inhibition results of compounds of general formula 1 by MTT assay on cancer cell line *In vitro cell line inhibition at 10µM: + indicates 30% to 50% of inhibition and ++ indicates greater than 50% of inhibition.
    DETAILED DESCRIPTION OF THE INVENTION
  • The present disclosure relates to newer generation of triazine based compounds, their method of preparation and to their use as drugs for treating cancer.
    Figure imgb0007
    Figure imgb0008
     In a first aspect, the present disclosure pertains to a compound having a general formula 1:
    Wherein substituent 'S1' is selected from one of the formula Ia or Ib
    Figure imgb0009
     and substituent 'S2' selected from the group consisting of 1c
    Figure imgb0010
     'X' is independently selected from any of NR3, O, CH2,
    'R1, R2' are independently selected from any of un/substituted alkyl C1-C14, un/substituted acyl C2 to C14, un/substituted phenyl ring and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl etc either mono or di or poly at any of the available position
    R3 is independently selected from any of H, un/substituted alkyl C1-C14, un/substituted acyl C2 to C14, un/substituted phenyl ring and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl etc either mono or di or poly at any of the available position
    Figure imgb0011
     is independently selected from any of following un/substituted N-heterocyles such as indolyl, triazolyl, pyrrolyl, imidazoyl, benzotriazolyl, benzoimidazolyl, thiazoyl etc attached though N-atom or any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl,
    'Ar' is independently selected from any of un/substituted phenyl, un/ substituted napthyl etc and attached through any of the available ring position and further substitution selected from any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl,
    'Hetero-Ar' is independently selected from any of un/substituted hetrocycles such as pyridyl, triazolyl, triazinyl, pyrimidinyl, pyridazinyl, oxazolyl, furanyl, benzofuranyl, thiophenyl, pyrrolyl, imidazoyl, thiazoyl, quinolinyl, isoquinolinyl, benzooxazolyl, and benzothiazolyl, indolyl, benzotriazolyl, benzoimidazolyl etc and attached through any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl,
    R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R14 and R17' are independently selected from any of following substitution such as H, linear alkyl chain C1-C10, branched alkyl chain C3-C10, un/substituted phenyl ring.
  • A preferred subclass have following formulas 1A or 1B belong to general formula 1
    Figure imgb0012
     'X' is independently selected from any of NR3, O, CH2,
    'R1, R2' are independently selected from any of following atom or groups un/substituted alkyl C1-C14, un/substituted acyl C2 to C14, un/substituted phenyl ring, un/substituted heterocycles and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3 COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl etc either mono or di or poly substituted at any of the available position
    R3 is independently selected from any of following atom or groups H, un/substituted alkyl C1-C14, un/substituted acyl C2 to C14, un/substituted phenyl ring, un/substituted heterocycles and further substitution contains any of the following atoms or groups such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3 COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl etc either mono or di or poly substituted at any of the available position
    Figure imgb0013
     is independently selected from any of following un/substituted N-heterocyles such as indolyl, triazolyl, pyrrolyl, imidazoyl, benzotriazolyl, benzoimidazolyl, thiazoyl etc attached though N-atom or any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl,
    'Ar' is independently selected from any of un/substituted phenyl, un/ substituted napthyl etc and attached through any of the available ring position and further substitution selected from any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl,
    'Hetero-Ar' is independently selected from any of un/substituted hetrocycles such as pyridyl, triazolyl, triazinyl, pyrimidinyl, pyridazinyl, oxazolyl, furanyl, benzofuranyl, thiophenyl, pyrrolyl, imidazoyl, thiazoyl, quinolinyl, isoquinolinyl, benzooxazolyl, and benzothiazolyl, indolyl, benzotriazolyl, benzoimidazolyl etc and attached through any of the available ring position and further substituted heterocycles contains any of the following atom or group such as F, Cl, Br, I, CN, NR4R5, CF3, CHCF2, CH2F, OCF3, OCH2CF3, OR6, NO2, NO, CHR7R8, alkyl chain from C1 to C14, COOR9, CHO, COR10, COCF3, COCH2CF3, SR11, SOR12, SO2R13, SONR14R15, SO2NR14R17, cycloalkyl,
    R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R14 and R17' are independently selected from any of following substitution such as H, linear alkyl chain C1-C10, branched alkyl chain C3-C10, un/substituted phenyl ring.
  • The compound of general formula 1 is useful as anti-cancer agent.
  • The compounds of formula 1A and 1B of general formula 1 inhibit PI3K α isoform.
  • The compounds of formula 1A and 1B of general formula 1 exhibit an in vitro cancer cell line activity.
  • The compound of formula 1A of general formula 1, wherein said compounds prepared by reacting di-substituted triazine compounds of formula (5) with substituted aryloxy piperidines (6) in an organic solvent N,N-dimethylformamide, in the presence of base potassium carbonate at a room temperature for 24 hrs to obtain the compounds of 1A (1-20) of general formula 1.
  • The compound of formula 1B of general formula 1, wherein said compounds prepared by reacting di-substituted triazine compounds of formula (8) with substituted aryloxy piperidines (6) in an organic solvent N,N-dimethylformamide in the presence of potassium carbonate at a room temperature for 24 hrs to obtain the compounds of 1B (1-20) of general formula 1.
  • These compounds, as well as mixtures thereof, isomers, physiologically functionally salt derivatives and drugs thereof, are useful in prevention of or therapy for treating cancer.
    Suitable acids for the preparation of the pharmaceutically acceptable salts, but are not limited to hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salyilic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid and methanesulfonic acid, boric acid, galactaric acid, gentisic acid, glucoheptonoic acid, D-gluconic acid, D-glucuronic acid, glycolic acid, hyppuric acid.
  • Suitable bases for the preparation of the pharmaceutically acceptable salts, but are not limited to sodium hydroxide, potassium hydroxide or ammonium hydroxide, ammonia, triethylamine, benethamine, benzathine, choline, deanol, isopropyl amine, L-lysine, L-arginine, morpholine, piperizine, pyrrolidine, pyridine quinoline, isoquinoline, triethanolamine.
  • The combination of the standard drugs, which are being prescribed presently for anticancer therapy along with the analogs of novel 1,3,5 substituted triazine scaffold with general formula 1, in various proportions and dosage, with the suitable pharmaceutical composition and formulation. The combination of the molecules that are reported as anticancer agents that may be derived from the natural sources viz. marine or terrestrial and the synthetic molecules along with the analogs of novel 1,3,5 substituted triazine scaffold with general formula 1, in various proportions and dosage, with the suitable pharmaceutical composition and formulation.
  • The compound of formula 1B of general formula 1, wherein said compounds prepared by reacting di substituted triazine compounds of formula (10) with substituted aryl amines (11) in an organic solvent DCM in the presence of acid acetic acid, and reducing agent like a sodium triacetoxy borohydride at a room temperature for 24 hrs to obtain the compounds of 1B (20-40) of general formula 1.
  • The compound of formula 1B of general formula 1, wherein said compounds prepared by reacting tri-substitued triazine compounds of formula (1B21) with substituted aryl boronic acids compounds of formula (12) in an organic solvent DCM in the presence of triethyl amine and copper acetate at a room temperature for 24 hrs to obtain the compounds of 1B (41-45) of general formula 1.
  • The compound of formula 1B of general formula 1, wherein said compounds prepared by reacting tri-substitued triazine compounds of formula (15) with substituted aryl amines of formula (11) in an organic solvent DCM in the presence of of acetic acid, and reducing agent sodium triacetoxy borohydride at a room temperature for 24 hrs to obtain the compounds of 1B (45-50) of general formula 1.
  • The present invention relates to the most highly preferred of the compounds of formula 1A and 1B, comprising of:
    • 4-(4-(4-fluorophenoxy)piperidin-1-yl)-N-methyl-6-morpholino-N-phenyl-1,3,5-triazin-2-amine (compound 1A1, Table 1)
    • 4-(4-(2-fluorophenoxy)piperidin-1-yl)-N-methyl-6-morpholino-N-phenyl-1,3,5-triazin-2-amine (compound 1A2, Table 1)
    • 4-(4-(4-fluorophenoxy)piperidin-1-yl)-N-(4-fluorophenyl)-N-methyl-6-morpholino-1,3,5-triazin-2-amine (compound 1A3, Table 1)
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide (compound 1A4, Table 1)
    • 2,2,2-trifluoro-N-(4-fluorophenyl)-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)acetamide (compound 1A5, Table 1)
    • 2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluoro phenyl)acetamide (compound 1A6, Table 1)
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide(compound 1A7, Table 1)
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide (compound 1A8, Table 1)
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide (compound 1A9, Table 1)
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide(compound 1A10, Table 1)
    • 2,2,2-trifluoro-N-methyl-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)acetamide (compound 1A11, Table 2)
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)-N-(2,2,2-trifluoro acetyl)acetamide (compound 1A12, Table 2)
    • 2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2,2,2-trifluoroacetyl)acetamide (compound 1A13, Table 2)
    • 2,2,2-trifluoro-N-(4-(4-(2-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2,2,2-trifluoroacetyl)acetamide (compound 1A14, Table 2)
    • 2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-methyl acetamide (compound 1A15, Table 2)
    • N,N-dimethyl-4-morpholino-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-amine (compound 1A16, Table 2)
    • 4-(4-(4-fluorophenoxy)piperidin-1-yl)-N,N-dimethyl-6-morpholino-1,3,5-triazin-2-amine (compound 1A17, Table 2)
    • 4-morpholino-6-(4-phenoxypiperidin-1-yl)-N,N-diphenyl-1,3,5-triazin-2-amine (compound 1A18, Table 2)
    • 4-morpholino-N,N-diphenyl-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-amine (compound 1A19, Table 2)
    • 4-morpholino-N,N-diphenyl-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-amine (compound 1A20, Table 2
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(4-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B1, Table 3)
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B2, Table 3)
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B3, Table 3)
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B4, Table 3)
    • 4-(4-(4-(4-chlorophenoxy)piperidin-1-yl)-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B5, Table 3)
    • 4-(4-(4-(3-chlorophenoxy)piperidin-1-yl)-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B6, Table 3)
    • 4-(4-(4-(2-chlorophenoxy)piperidin-1-yl)-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B7, Table 3)
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(3-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B8, Table 3)
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(2-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B9, Table 3)
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B10, Table 3)
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(m-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B11, Table 4)
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(o-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B12, Table 4)
    • 4-(4-(5-fluoro-1H-benzo[d]imidazol-1-yl)-6-(4-(p-tolyloxy)piperdin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B13, Table 4)
    • 4-(4-(5-fluoro-1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B14, Table 4)
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B15, Table 4)
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B16, Table 4)
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(4-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B17, Table 4)
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(2-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B18, Table 4)
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(2-chlorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B19, Table 4)
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B20, Table 4)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluoro phenyl)piperidin-4-amine (compound 1B21, Table 5)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B22, Table 5)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B23, Table 5)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-methoxy phenyl)piperidin-4-amine (compound 1B24, Table 5)
    • N-(4-bromophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine (compound 1B25, Table 5)
    • N-(3,4-dichlorophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine (compound 1B26, Table 5)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-fluoro phenyl)piperidin-4-amine (compound 1B27, Table 5)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-methoxy phenyl)piperidin-4-amine (compound 1B28, Table 5)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B29, Table 5)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(p-tolyl) piperidin-4-amine (compound 1B30, Table 5)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(3-methoxy phenyl)piperidin-4-amine (compound 1B31, Table 5)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(o-tolyl) piperidin-4-amine (compound 1B32, Table 6)
    • 1-(4-(2-(difluoromethyl)-5-fluoro-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(p-tolyl)piperidin-4-amine (compound 1B33, Table 6)
    • 1-(4-(2-(difluoromethyl)-5-fluoro-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoromethyl)phenyl)piperidin-4-amine (compound 1B34, Table 6)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B35, Table 6)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B36, Table 6)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluoro phenyl)piperidin-4-amine (compound 1B37, Table 6)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-fluoro phenyl)piperidin-4-amine (compound 1B38, Table 6)
    • N-(2-chlorophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine (compound 1B39, Table 6)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B40, Table 6)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N,N-bis(4-fluorophenyl)piperidin-4-amine (compound 1B41, Table 7)
    • N-(4-bromophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)piperidin-4-amine (compound 1B42, Table 7)
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)-N-(4-(trifluoromethyl)phenyl)piperidin-4-amine(compound 1B43, Table 7)
    • N-(4-chlorophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)piperidin-4-amine (compound 1B44, Table 7)
    • N-(1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-yl)-N-(4-fluorophenyl)-3-(trifluoromethyl)pyridin-4-amine(compound1B45, Table 7)
    • 1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluoro phenyl)piperidin-4-amine (compound 1B46, Table 7)
    • 1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-methoxy phenyl)piperidin-4-amine (compound 1B47, Table 7)
    • 1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B48, Table 7)
    • 1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B49, Table 7)
    • N-(4-chlorophenyl)-1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine (compound 1B50, Table 7)
  • The invention is further described by reference to following examples which are intended to illustrate, not to limit the scope of the invention.
    • Example 1: General procedure for the preparation of compounds (IA1-20):
  • Cynuric chloride (1) (10g, 54.2 mmol, 1.0 eq) was substituted by morpholine (7) (4.72 ml, 5.42 mmol, 1.0 eq) in methylene chloride (60 ml), at -50 °C for 20 min to obtain intermediate (3). The intermediate (3) (5 g, 1.0 eq) on further treatment with di-substitued amine (4) (1.4 eq) in presence of K2CO3 (1.44 eq) in DMF (20 ml) , at -5 °C for 30 min and then at room temperature for 4 h led to intermediate (5) . To the solution of intermediate (5) (100 mg, 1.0 eq) in DMF (3 ml) were added K2CO3 (1.4 eq) and substituted aryloxy piperidines (6) (1.44 eq).This resulting reaction mixture was stirred at room temperature for 24 h. The thus-obtained mixture was poured into water (30 ml) and extracted with ethyl acetate twice washed with 2N HCl solution and dried under vacuo. This crude product was purified by silica gel column chromatography using a ethyl acetate and hexane mixture as solvent to obtained the compound of formula 1A(1-20).
    • Example 2: General procedure for the preparation of compounds (IB1-20):
  • Cynuric chloride (1) (10g, 54.2 mmol, 1.0 eq) was substituted by morpholine (7) (4.72 ml, 5.42 mmol, 1.0 eq) in methylene chloride (60 ml), at -50 °C for 20 min to obtain intermediate (3). The intermediate (3) (5 g, 1.0 eq) on further treatment with di-substitued benzimidazole (7) (1.4 eq) in presence of K2CO3 (1.44 eq) in DMF (20 ml) , at -5 °C for 30 min and then at room temperature for 4 h led to intermediate (8) . To the solution of intermediate (8) (100 mg, 1.0 eq) in DMF (3 ml) are added K2CO3 (1.4 eq) and substituted aryloxy piperidines (6) (1.44 eq).This resulting reaction mixture was stirred at room temperature for 24 h. The thus-obtained mixture was poured into water (30 ml) and extracted with ethyl acetate twice washed with 2N HCl solution and dried under vacuo. This crude product was purified by silica gel column chromatography using an ethyl acetate and hexane mixture as solvent to obtained the compounds formula (1B1-20).
    • Example 3: General procedure for the preparation of compounds (IB21-40):
  • The intermediate (8) (5 g, 1.0 eq) on reaction with piperidone (9) (1.4 eq) in presence of K2CO3 (1.44 eq) in DMF (20 ml), at room temperature for 24 h led to the formation of intermediate (10). To the solution of intermediate (10) (100 mg, 1.0 eq) in dichloromethane (3 ml) are added acetic acid (1 eq) and substituted primary aromatic amines (11) (1 eq). This resulting reaction mixture was stirred at room temperature for 6 h and then added Sodium triacetoxy borohydride (Na(OAC)3BH) (1 eq).This resulting reaction mixture again stirred at room temperature for 24 h. The thus-obtain mixture was poured into water (30 ml) and extracted with ethyl acetate and dried under vacuo. This crude product was purified by silica gel column chromatography using an ethyl acetate and hexane mixture as solvent to obtain the compounds of formula (1B21-40).
    • Example 4: General procedure for the preparation of compounds (IB41-45):
  • Take the (IB21) (100 mg, 1.0 eq) on reaction with substituted aryl boronic acid (12) (2 eq) and copper acetate (20 mole %) in dichloromethane solvent at room temperature. To this reaction mixture added the triethylamine (1 eq). This resulting mixture stirred at room temperature for 24 h. The thus-obtained mixture was poured into water (30 ml) and extracted with ethyl acetate and dried under vacuo. This crude product was purified by silica gel column chromatography using an ethyl acetate and hexane mixture as solvent to obtained the compounds formula (1B41-45).
    • Example 5: General procedure for the preparation of compounds (IB46-50):
  • Cynuric chloride (1) (10g, 54.2 mmol, 1.0 eq) was substituted by morpholine (7) (4.72 ml, 5.42 mmol, 1.0 eq) in methylene chloride (60 ml), at -50 °C for 20 min to obtain intermediate (3). The intermediate (3) (5 g, 1.0 eq) on further treatment with substitued indole (13) (1.4 eq) in presence of K2CO3 (1.44 eq) in DMF (20 ml) , at -5 °C for 30 min and further stirring at room temperature for 4 h led to intermediate (14). The intermediate (14) (5 g, 1.0 eq) on reaction with piperidone (9) (1.4 eq) in presence of K2CO3 (1.44 eq) in DMF (20 ml), at room temperature for 24 h led to intermediate (15). To the solution of intermediate (15) (100 mg, 1.0 eq) in Dichloromethane (3ml) are added acetic acid (1 eq) and substituted primary aromatic amines (11) (1 eq). This resulting reaction mixture was stirred at room temperature for 6h and then added Sodium triacetoxy borohydride (Na(OAC)3BH) (1 eq). This resulting mixture was stirred again at room temperature for 24 h. The thus-obtained mixture was poured into water (30 ml) and extracted with ethyl acetate and dried under vacuo. This crude product was purified by silica gel column chromatography using an ethyl acetate and hexane mixture as solvent to obtain the compounds of formula (1B46-50).
    • 4-(4-(4-fluorophenoxy)piperidin-1-yl)-N-methyl-6-morpholino-N-phenyl-1,3,5-triazin-2-amine (compound 1A1, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.26 (t, J = 7.5 Hz, 2H), 7.08 - 6.91 (m, 7H), 4.53 - 4.43 (m, 1H), 3.77 (t, J = 4.9 Hz, 4H), 3.52 - 3.42 (m, 4H), 3.40 (t, J = 4.8 Hz, 2H), 3.32 (dt, J = 12.3, 5.3 Hz, 2H), 2.15 (dqd, J = 12.7, 5.4, 2.3 Hz, 2H), 1.88 (dqd, J = 12.8, 5.4, 2.2 Hz, 2H) Mass: ESI [M+ 1] : 465.
    • 4-(4-(2-fluorophenoxy)piperidin-1-yl)-N-methyl-6-morpholino-N-phenyl-1,3,5-triazin-2-amine(compound 1A2, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.26 (t, J = 7.5 Hz, 2H), 7.09 - 6.84 (m, 7H), 4.31 (p, J = 7.2 Hz, 1H), 3.53 (t, J = 4.9 Hz, 2H), 3.39 (ddq, J = 64.5, 12.3, 6.1 Hz, 6H), 2.34 - 2.20 (m, 2H), 1.92 (qd, J = 12.4, 6.1 Hz, 2H) Mass: ESI [M+ 1] : 465.
    • 4-(4-(4-fluorophenoxy)piperidin-1-yl)-N-(4-fluorophenyl)-N-methyl-6-morpholino-1,3,5-triazin-2-amine(compound 1A3, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.09 - 6.87 (m, 8H), 4.54 - 4.40 (m, 1H), 3.77 (t, J = 4.8 Hz, 4H), 3.52 - 3.24 (m, 8H), 3.01 (s, 3H), 2.20 - 2.07 (m, 2H), 1.99 - 1.80 (m, 2H) Mass: ESI [M+ 1] : 483.
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide(compound 1A4, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.14 (m, 6H), 7.14 - 6.80 (m, 4H), 4.39 (tt, J = 7.9, 3.8 Hz, 1H), 3.79 (t, J = 4.8 Hz, 4H), 3.54 (t, J = 4.9 Hz, 2H), 3.47 - 3.20 (m, 6H), 2.30 - 2.12 (m, 2H), 1.90 (dqd, J = 11.1, 5.4, 1.9 Hz, 2H) Mass: ESI [M+ 1] : 529.
    • 2,2,2-trifluoro-N-(4-fluorophenyl)-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)acetamide(compound 1A5, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.14 (m, 4H), 7.09 (t, J = 7.8 Hz, 2H), 6.99 - 6.82 (m, 3H), 4.38 (tt, J = 8.0, 4.0 Hz, 1H), 3.59 - 3.37 (m, 6H), 3.29 (dt, J = 12.3, 5.3 Hz, 2H), 2.27 - 2.10 (m, 2H), 1.91 (tdd, J = 11.4, 5.4, 1.8 Hz, 2H) Mass: ESI [M + 1] : 547.
    • 2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)acetamide(compound 1A6, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.31 - 7.19 (m, 2H), 7.04 (dt, J = 49.3, 7.8 Hz, 4H), 6.94 - 6.79 (m, 2H), 4.09 (p, J = 7.4 Hz, 1H), 3.78 (t, J = 4.9 Hz, 4H), 3.57 - 3.37 (m, 6H), 3.21 (dt, J = 12.2, 5.5 Hz, 2H), 2.14 (ddt, J = 12.9, 7.5, 5.5 Hz, 2H), 1.92 (ddt, J = 12.8, 7.5, 5.5 Hz, 2H) Mass: ESI [M+ 1] : 565.
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide(compound 1A7, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 7.5 Hz, 2H), 7.42 - 7.21 (m, 4H), 7.14 - 7.04 (m, 1H), 6.87 (d, J = 7.5 Hz, 2H), 4.40 (tt, J = 8.0, 4.0 Hz, 1H), 3.79 (t, J = 4.8 Hz, 4H), 3.54 (t, J = 4.8 Hz, 2H), 3.45 - 3.18 (m, 6H), 2.32 - 2.10 (m, 2H), 1.99 - 1.80 (m, 2H) Mass: ESI [M+ 1] : 597.
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide(compound 1A8, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.21 (m, 4H), 7.17 - 7.02 (m, 3H), 6.84 (d, J = 7.5 Hz, 2H), 4.08 (p, J = 7.4 Hz, 1H), 3.78 (t, J = 4.9 Hz, 4H), 3.59 - 3.39 (m, 6H), 3.19 (dt, J = 12.4, 5.5 Hz, 2H), 2.32 (s, 3H), 2.19 (ddt, J = 12.9, 7.5, 5.5 Hz, 2H), 1.95 (ddt, J = 12.9, 7.5, 5.6 Hz, 2H) Mass: ESI [ M+ 1] : 543.
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide(compound 1A9, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.21 (m, 4H), 7.14 - 7.06 (m, 1H), 6.95 (dd, J = 39.7, 7.5 Hz, 4H), 4.38 (tt, J = 8.0, 4.1 Hz, 1H), 3.78 (t, J= 4.9 Hz, 4H), 3.57 - 3.36 (m, 6H), 3.29 (dt, J = 12.3, 5.4 Hz, 2H), 2.30 - 2.10 (m, 2H), 1.99 - 1.80 (m, 2H) Mass: ESI [M+ 1] : 613.
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide(compound 1A10, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.56 (dd, J = 7.4, 1.5 Hz, 1H), 7.31 (ddd, J = 33.5, 7.5, 1.4 Hz, 5H), 7.17 - 6.89 (m, 3H), 4.68 (p, J = 3.1 Hz, 1H), 3.78 (t, J = 4.9 Hz, 4H), 3.59 - 3.32 (m, 6H), 3.18 (dt, J = 12.4, 5.6 Hz, 2H), 2.22 (dtd, J = 12.2, 5.6, 2.9 Hz, 2H), 2.00 (dtd, J = 12.4, 5.6, 2.9 Hz, 2H) Mass: ESI [M+ 1] : 597.
    • 2,2,2-trifluoro-N-methyl-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)acetamide(compound 1A11, Table 2, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.26 (t, J = 7.5 Hz, 2H), 7.06 - 6.86 (m, 3H), 4.14 (p, J = 7.5 Hz, 1H), 3.78 (t, J = 4.9 Hz, 4H), 3.57 - 3.39 (m, 6H), 3.32 (s, 3H), 3.20 (dt, J = 12.4, 5.7 Hz, 2H), 2.22 - 2.05 (m, 2H), 2.00 - 1.87 (m, 2H) Mass: ESI [M+1] : 467.
    • 2,2,2-trifluoro-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)- N -(2,2,2-trifluoroacetyl)acetamide(compound 1A12, Table 2, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.23 (t, J = 7.5 Hz, 2H), 6.99 - 6.79 (m, 3H), 4.38 (tt, J = 7.6, 3.7 Hz, 1H), 3.78 (t, J = 4.9 Hz, 4H), 3.55 - 3.34 (m, 6H), 3.29 (dt, J = 12.4, 5.3 Hz, 2H), 2.28 - 2.05 (m, 2H), 2.00 - 1.77 (m, 2H) Mass: ESI [M + 1] : 549.
    • 2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2,2,2-trifluoroacetyl)acetamide(compound 1A13, Table 2, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.11 - 6.84 (m, 4H), 4.12 (p, J = 7.6 Hz, 1H), 3.78 (t, J = 4.8 Hz, 4H), 3.54 - 3.34 (m, 6H), 3.21 (dt, J = 12.3, 5.6 Hz, 2H), 2.14 (ddt, J = 13.0, 7.6, 5.5 Hz, 2H), 1.95 (ddt, J = 13.0, 7.6, 5.6 Hz, 2H) Mass: ESI [M + 1] : 567.
    • 2,2,2-trifluoro-N-(4-(4-(2-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2,2,2-trifluoroacetyl)acetamide(compound 1A14, Table 2, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.14 - 6.82 (m, 4H), 4.26 (p, J = 7.6 Hz, 1H), 3.78 (t, J = 4.9 Hz, 4H), 3.60 - 3.34 (m, 6H), 3.18 (dt, J = 12.4, 5.5 Hz, 2H), 2.17 (ddt, J = 12.9, 7.5, 5.5 Hz, 2H), 2.00 (ddt, J = 12.8, 7.5, 5.5 Hz, 2H) Mass: ESI [M + 1] : 567.
    • 2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-methylacetamide(compound 1A15, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.01 (t, J = 7.7 Hz, 2H), 6.96 - 6.88 (m, 2H), 4.61 - 4.52 (m, 1H), 3.78 (t, J = 4.8 Hz, 4H), 3.56 - 3.41 (m, 6H), 3.39 - 3.31 (m, 5H), 2.22 (dqd, J = 12.9, 5.4, 2.3 Hz, 2H), 1.94 (dqd, J = 12.9, 5.4, 2.3 Hz, 2H) Mass: ESI [M + 1] : 485.
    • N,N-dimethyl-4-morpholino-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-amine (compound 1A16, Table 1, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.12 (d, J = 7.5 Hz, 2H), 6.85 (d, J = 7.5 Hz, 2H), 4.43 - 4.34 (m, 1H), 3.78 (t, J = 4.8 Hz, 4H), 3.52 (t, J = 4.9 Hz, 2H), 3.48 - 3.39 (m, 4H), 3.30 (dt, J = 12.4, 5.3 Hz, 2H), 2.99 (s, 6H), 2.33 (s, 3H), 2.24 - 2.13 (m, 2H), 1.89 (dqd, J = 12.8, 5.4, 2.0 Hz, 2H) Mass: ESI [M + 1] : 399.
    • 4-(4-(4-fluorophenoxy)piperidin-1-yl)-N,N-dimethyl-6-morpholino-1,3,5-triazin-2-amine (compound 1A17, Table 2, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.12 (d, J = 7.5 Hz, 2H), 6.85 (d, J = 7.5 Hz, 2H), 4.43 - 4.34 (m, 1H), 3.78 (t, J = 4.8 Hz, 4H), 3.52 (t, J = 4.9 Hz, 2H), 3.48 - 3.39 (m, 4H), 3.30 (dt, J = 12.4, 5.3 Hz, 2H), 2.99 (s, 6H), 2.24 - 2.13 (m, 2H), 1.89 (dqd, J = 12.8, 5.4, 2.0 Hz Mass: ESI [M+ 1] : 403.
    • 4-morpholino-6-(4-phenoxypiperidin-1-yl)-N,N-diphenyl-1,3,5-triazin-2-amine (compound 1A18, Table 2, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.25 (td, J = 7.7, 1.1 Hz, 6H), 7.04 - 6.86 (m, 9H), 4.50 - 4.41 (m, 1H), 3.44 (ddd, J = 14.0, 10.1, 5.0 Hz, 4H), 3.32 (dt, J = 12.3, 5.3 Hz, 2H), 3.98 - 2.00 (m, 14H), 3.51 - 2.00 (m, 8H), 2.17 (dqd, J = 12.9, 5.4, 2.2 Hz, 2H), 1.91 (dqd, J = 12.8, 5.4, 2.2 Hz, 2H) Mass: ESI [ M + 1] : 509.
    • 4-morpholino-N,N-diphenyl-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-amine(compound 1A19, Table 2, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 7.4, 1.5 Hz, 1H), 7.33 - 7.21 (m, 5H), 7.05 - 6.86 (m, 8H), 4.10 (p, J = 7.5 Hz, 1H), 3.78 (t, J = 4.5 Hz, 4H), 3.58 - 3.49 (m, 4H), 3.40 (t, J = 4.5 Hz, 2H), 3.20 (dt, J = 12.3, 5.4 Hz, 2H), 2.19 (ddt, J = 12.8, 7.4, 5.5 Hz, 2H), 1.94 (ddt, J = 12.8, 7.4, 5.5 Hz, 2H) Mass: ESI [M + 1] : 577.
    • 4-morpholino-N,N-diphenyl-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-amine(compound 1A20, Table 2, Fig 1)
  • 1H NMR (400 MHz, CDCl3) δ 7.26 (t, J = 7.5 Hz, 4H), 7.05 - 6.94 (m, 6H), 6.89 (q, J = 7.5 Hz, 4H), 4.48 (p, J = 2.7 Hz, 1H), 3.78 (t, J = 4.8 Hz, 4H), 3.56 - 3.41 (m, 6H), 3.30 (dt, J = 12.4, 5.4 Hz, 2H), 2.13 (dtd, J = 12.4, 5.4, 2.8 Hz, 2H), 1.87 (dtd, J = 12.4, 5.4, 2.8 Hz, 2H) Mass: ESI [M+ 1] : 593.
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(4-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B1, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.35 (dd, J = 7.2, 1.2 Hz, 1H), 7.89 (d, J = 7.4 Hz, 1H), 7.65 (d, J = 53.7 Hz, 1H), 7.49 - 7.33 (m, 2H), 7.07 - 6.83 (m, 4H), 4.53 (tt, J = 6.2, 3.1 Hz, 1H), 4.06 (d, J = 4.8 Hz, 2H), 3.84 (dd, J = 33.6, 4.7 Hz, 10H), 1.95 (d, J = 40.2 Hz, 4H). Mass: ESI [M+ 1] : 526.
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B2, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) : δ8.36 (d, J = 8 Hz, 1H), 7.90 (d, J = 8 Hz, 1H), 7.73 (t, J = 54, 1H), 7.45 (m, 2H), 6.92 (m, 4H), 4.50 (m, 1H), 4.08 (d, J = 4 Hz, 2H), 3.89 (dd, J = 6 Hz, J = 39 Hz, 13H,), 1.99 (dd, J = 1 Hz, J = 31 Hz, 4H). Mass: ESI [M+ 1] : 538.
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethoxy)phenoxy) piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B3, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ8.36 (d, J = 8 Hz, 1H), 7.90 (d, J = 8 Hz, 1H), 7.73 (t, J = 54, 1H), 7.45 (m, 2H), 6.92 (m, 4H), 4.50 (m, 1H), 4.08 (d, J = 4 Hz, 2H), 3.89 (dd, J = 6 Hz, J = 39 Hz, 13H,), 1.99 (dd, J = 1 Hz, J = 31 Hz, 4H). Mass: ESI [M+ 1] :592.
    • 4-(4-(2-(difluoromethyl)- 1H-benzo[d]imidazol-1-yl)-6-(4-(2-(trifluoromethyl)phenoxy )piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B4, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 7.1 Hz, 1H), 7.67 (d, J = 41.7 Hz, 1H), 7.59 (d, J = 3.9 Hz, 1H), 7.54 - 7.35 (m, 3H), 7.01 (dd, J = 15.2, 8.7 Hz, 2H), 4.91 - 4.71 (m, 1H), 4.22 (d, J = 10.4 Hz, 2H), 3.84 (d, J = 35.7 Hz, 9H), 2.00 (dd, J = 25.1, 14.4 Hz, 4H). Mass: ESI [M + 1] :576.
    • 4-(4-(4-(4-chlorophenoxy)piperidin-1-yl)-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B5, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 7.2 Hz, 1H), 7.89 (d, J = 7.0 Hz, 1H), 7.65 (d, J = 53.6 Hz, 1H), 7.50 - 7.33 (m, 2H), 7.29 - 7.23 (m, 2H), 6.88 (dd, J = 6.6, 2.3 Hz, 2H), 4.62 - 4.52 (m, 1H), 4.05 (d, J = 2.1 Hz, 2H), 3.84 (d, J = 36.6 Hz, 9H), 1.96 (d, J = 39.3 Hz, 4H). Mass: ESI [M+ 1] :542.
    • 4-(4-(4-(3-chlorophenoxy)piperidin-1-yl)-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B6, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 7.6 Hz, 1H), 7.89 (d, J = 7.4 Hz, 1H), 7.66 (d, J = 53.6 Hz, 1H), 7.46 - 7.36 (m, 2H), 7.22 (t, J = 8.4 Hz, 1H), 6.99 - 6.94 (m, 2H), 6.84 (d, J = 9.2 Hz, 1H), 4.61 (dd, J = 6.1, 3.0 Hz, 1H), 4.15 - 3.97 (m, 2H), 3.89 (ddd, J = 37.4, 19.6, 4.2 Hz, 10H), 1.97 (d, J = 34.7 Hz, 4H). Mass: ESI [M+ 1] : 542.
    • 4-(4-(4-(2-ehlorophenoxy)piperidin-1-yl)-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B7, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.36 (d, J = 7.4 Hz, 2H), 7.88 (d, J = 6.9 Hz, 2H), 7.66 (d, J = 53.6 Hz, 2H), 7.50 - 7.28 (m, 7H), 7.22 (t, J = 12.5 Hz, 2H), 7.06 - 6.84 (m, 4H), 4.80 - 4.61 (m, 2H), 4.03 (d, J = 24.4 Hz, 8H), 3.83 (d, J = 34.1 Hz, 15H), 1.99 (s, 8H). Mass: ESI [M + 1] :542.
    • 4-(4-(2-(difluoromethyl)- 1H-benzo[d]imidazol-1-yl)-6-(4-(3-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B8, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 7.6 Hz, 1H), 7.89 (d, J = 7.4 Hz, 1H), 7.66 (d, J = 53.6 Hz, 1H), 7.46 - 7.36 (m, 2H), 7.22 (t, J = 8.4 Hz, 1H), 6.99 - 6.94 (m, 2H), 6.84 (d, J = 9.2 Hz, 1H), 4.61 (dd, J = 6.1, 3.0 Hz, 1H), 4.15 - 3.97 (m, 2H), 3.89 (ddd, J = 37.4, 19.6, 4.2 Hz, 10H), 1.97 (d, J = 34.7 Hz, 4H). Mass: ESI [M + 1] : 526.
    • 4-(4-(2-(difluoromethyl)- 1H-benzo[d]imidazol-1-yl)-6-(4-(2-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B9, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) : δ8.36 (d, J=8 Hz, 1H), 7.90 (d, J=8 Hz, 1H), 7.73 (t, J=54, 1H), 7.45 (m, 2H), 7.21 (d, J=3Hz, 1H), 7.01 (d, J=3Hz, 1H), 6.96 (m, 2H), 4.50 (m, 1H), 4.08 (d, J=4 Hz, 2H), 3.89 (dd, J=6 Hz, J=39 Hz, 10H), 1.99 (dd, J=1 Hz, J=31 Hz, 4H). Mass: ESI [M + 1] :526.
    • 4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B10, Table 3, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 7.5 Hz, 1H), 7.89 (d, J = 7.3 Hz, 1H), 7.66 (d, J = 53.6 Hz, 1H), 7.43 - 7.35 (m, 2H), 7.11 (d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 4.65 - 4.48 (m, 1H), 4.15 - 3.98 (m, 2H), 3.87 (t, J = 25.4 Hz, 9H), 2.30 (s, 3H), 2.05 - 1.87 (m, 4H). Mass: ESI [M + 1] :522.
    • 4-(4-(2-(difluoromethyl)- 1H-benzo[d]imidazol-1-yl)-6-(4-(m-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B11, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 7.4 Hz, 1H), 7.65 (d, J = 53.6 Hz, 1H), 7.46 - 7.34 (m, 2H), 7.18 (t, J = 7.9 Hz, 1H), 6.77 (dd, J = 13.9, 8.3 Hz, 3H), 4.60 (dd, J = 6.0, 3.0 Hz, 1H), 4.13 - 3.98 (m, 2H), 3.88 (ddd, J = 35.9, 18.7, 4.2 Hz, 10H), 2.34 (s, 3H), 1.96 (d, J = 30.2 Hz, 4H). Mass: ESI [M+ 1] :522.
    • 4-(4-(2-(difluoromethyl)- 1H-benzo[d]imidazol-1-yl)-6-(4-(o-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B12, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 7.4 Hz, 1H), 7.89 (d, J = 7.2 Hz, 1H), 7.65 (d, J = 53.6 Hz, 1H), 7.49 - 7.33 (m, 2H), 7.11 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 4.57 (dq, J = 9.3, 3.2 Hz, 1H), 4.15 - 3.97 (m, 2H), 3.86 (ddd, J = 37.4, 7.5, 4.1 Hz, 10H), 2.29 (d, J = 14.1 Hz, 3H), 1.96 (dd, J = 29.1, 3.9 Hz, 4H). Mass: ESI [M+ 1] :522.
    • 4-(4-(5-fluoro-1H-benzo[d]imidazol-1-yl)-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B13, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.79 (dd, J = 7.5, 5.0 Hz, 1H), 7.43 (dd, J = 8.0, 1.5 Hz, 1H), 7.13 - 7.04 (m, 3H), 6.82 (d, J = 7.5 Hz, 2H), 4.42 (tt, J = 7.8, 3.8 Hz, 1H), 3.79 (t, J = 4.9 Hz, 4H), 3.55 - 3.41 (m, 6H), 3.32 (dt, J = 12.4, 5.3 Hz, 2H), 2.31 (s, 3H), 2.30 - 2.19 (m, 2H), 2.01 - 1.90 (m, 2H) Mass: ESI [M + 1] : 490.
    • 4-(4-(5-fluoro-1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B14, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.48 (s, 1H), 7.83 (dd, J = 7.5, 5.0 Hz, 1H), 7.49 (dd, J = 7.9, 1.5 Hz, 3H), 7.07 (td, J = 7.8, 1.5 Hz, 1H), 6.88 (d, J = 7.4 Hz, 2H), 4.41 (p, J = 7.0 Hz, 1H), 3.79 (t, J = 4.8 Hz, 4H), 3.58 - 3.41 (m, 6H), 3.39 - 3.28 (m, 2H), 2.29 (td, J = 12.8, 6.0 Hz, 2H), 1.95 (td, J = 12.8, 6.0 Hz, 2H) Mass: ESI [M + 1] : 544.
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B15, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 8.14 - 7.76 (m, 1H), 7.74 - 7.61 (m, 1H), 7.49 (d, J = 7.4 Hz, 2H), 7.37 - 7.23 (m, 2H), 6.88 (d, J = 7.4 Hz, 2H), 4.41 (p, J = 7.1 Hz, 1H), 3.79 (t, J = 4.8 Hz, 4H), 3.58 - 3.41 (m, 6H), 3.33 (dt, J = 12.1, 5.9 Hz, 2H), 2.29 (td, J = 12.7, 5.9 Hz, 2H), 1.95 (td, J = 12.6, 5.9 Hz, 2H) Mass: ESI [M + 1] : 526.
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B16, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 8.15 - 7.76 (m, 1H), 7.74 - 7.38 (m, 1H), 7.36 - 7.23 (m, 2H), 6.95 - 6.83 (m, 4H), 4.41 (p, J = 7.0 Hz, 1H), 3.79 (t, J = 4.8 Hz, 4H), 3.58 - 3.41 (m, 6H), 3.33 (dt, J = 12.2, 5.9 Hz, 2H), 2.29 (td, J = 12.7, 5.9 Hz, 2H), 1.95 (td, J = 12.7, 5.9 Hz, 2H) Mass: ESI [ M+ 1] : 542.
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(4-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl) morpholine(compound 1B17, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 8.13 - 7.73 (m, 1H), 7.69 - 7.52 (m, 1H), 7.29 (dtd, J = 20.1, 7.4, 1.6 Hz, 2H), 6.97 (t, J = 7.8 Hz, 2H), 6.91 - 6.80 (m, 2H), 4.45 (tt, J = 7.8, 4.0 Hz, 1H), 3.78 (t, J = 4.8 Hz, 4H), 3.57 - 3.40 (m, 6H), 3.33 (dt, J = 12.4, 5.3 Hz, 2H), 2.28 (dqd, J = 11.1, 5.4, 1.9 Hz, 2H), 1.97 (dqd, J = 11.2, 5.5, 1.9 Hz, 2H) Mass: ESI [M + 1] : 476.
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(2-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl) morpholine(compound 1B18, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.55 - 7.71 (m, 2H), 7.68 - 7.52 (m, 1H), 7.29 (dtd, J = 19.3, 7.4, 1.6 Hz, 2H), 7.03 - 6.81 (m, 4H), 4.83 (tt, J = 7.8, 3.9 Hz, 1H), 3.79 (t, J = 4.9 Hz, 4H), 3.56 - 3.40 (m, 6H), 3.32 (dt, J = 12.4, 5.3 Hz, 2H), 2.28 (dqd, J = 11.1, 5.4, 1.8 Hz, 2H), 1.94 (dqd, J = 11.1, 5.4, 1.8 Hz, 2H) Mass: ESI [M + 1] : 476.
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(2-chlorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl) morpholine(compound 1B19, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.15 (s, 1H), 7.90 - 7.73 (m, 1H), 7.69 - 7.52 (m, 1H), 7.37 - 7.22 (m, 3H), 7.14 (td, J = 7.5, 1.5 Hz, 1H), 7.09 - 6.31 (m, 2H), 4.71 (p, J = 7.2 Hz, 1H), 3.78 (t, J = 4.8 Hz, 4H), 3.57 - 3.40 (m, 6H), 3.33 (dt, J = 12.2, 6.0 Hz, 2H), 2.28 (ddd, J = 18.6, 10.1, 6.0 Hz, 2H), 1.96 (ddd, J = 12.3, 10.1, 6.0 Hz, 2H) Mass: ESI [M+ 1] : 492.
    • 4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine(compound 1B20, Table 4, Fig 2)
  • 1H NMR (400 MHz, CDCl3) δ 8.47 (s, 1H), 8.14 - 7.76 (m, 1H), 7.74 - 7.62 (m, 1H), 7.54 (dd, J = 7.5, 1.4 Hz, 1H), 7.37 - 7.23 (m, 3H), 7.05 - 6.93 (m, 2H), 4.25 (p, J = 7.5 Hz, 1H), 3.79 (t, J = 4.8 Hz, 4H), 3.58 - 3.42 (m, 6H), 3.20 (dt, J = 12.3, 5.4 Hz, 2H), 2.36 (ddt, J = 12.8, 7.4, 5.4 Hz, 2H), 2.00 (ddt, J = 12.9, 7.5, 5.5 Hz, 2H) Mass: ESI [M + 1] : 526.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluoro phenyl)piperidin-4-amine(compound 1B21, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 8.2 Hz, 1H), 7.89 (d, J = 7.3 Hz, 1H), 7.65 (d, J = 53.7 Hz, 1H), 7.41 (dt, J = 13.7, 5.8 Hz, 2H), 6.92 (t, J = 8.6 Hz, 2H), 6.75 - 6.50 (m, 2H), 4.69 (d, J = 10.4 Hz, 2H), 3.84 (m, 8H), 3.64 - 3.44 (m, 1H), 3.33 - 3.03 (m, 1H), 2.20 (dd, J = 12.2, 9.5 Hz, 2H), 1.45 (dd, J = 21.1, 9.9 Hz, 2H). Mass: ESI [M+ 1] :525.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(tri fluoromethyl)phenyl)piperidin-4-amine(compound 1B22, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 8.8 Hz, 1H), 7.90 (d, J = 8.3 Hz, 1H), 7.65 (d, J = 53.7 Hz, 1H), 7.53 - 7.28 (m, 4H), 6.64 (d, J = 8.6 Hz, 2H), 4.78 - 4.58 (m, 2H), 3.84 (dd, J = 34.4, 4.2 Hz, 8H), 3.71 - 3.58 (m, 1H), 3.36 - 3.12 (m, 2H), 2.22 (td, J = 10.7, 5.4 Hz, 2H), 1.51 - 1.35 (m, 2H). Mass: ESI [M+ 1] : 575.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(tri fluoromethoxy)phenyl)piperidin-4-amine(compound compound 1B23, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 7.4 Hz, 1H), 7.90 (d, J = 7.2 Hz, 1H), 7.65 (d, J = 53.7 Hz, 1H), 7.48 - 7.35 (m, 2H), 7.05 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 8.9 Hz, 2H), 4.69 (d, J = 9.2 Hz, 2H), 3.84 (dd, J = 34.0, 3.7 Hz, 8H), 3.64 - 3.52 (m, 1H), 3.23 (dt, J = 17.6, 7.5 Hz, 2H), 2.21 (t, J = 11.4 Hz, 2H), 1.45 (dd, J = 22.7, 11.7 Hz, 2H). Mass: ESI [M+ 1]:591.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-meth oxyphenyl)piperidin-4-amine(compound compound 1B24, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 7.6 Hz, 1H), 7.89 (d, J = 7.3 Hz, 1H), 7.65 (d, J = 53.6 Hz, 1H), 7.48 - 7.33 (m, 2H), 6.80 (d, J = 8.8 Hz, 2H), 6.65 (d, J = 8.7 Hz, 2H), 4.79 - 4.53 (m, 2H), 3.88 (d, J = 4.4 Hz, 4H), 3.80 (d, J = 4.1 Hz, 4H), 3.76 (s, 3H), 3.55 - 3.48 (m, 1H), 3.21 (dt, J = 23.5, 11.7 Hz, 2H), 2.18 (dd, J = 14.8, 9.0 Hz, 2H), 1.46 - 1.37 (m, 2H). Mass: ESI [M+ 1] :537.
    • N-(4-bromophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine(compound compound 1B25, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.65 (d, J = 53.6 Hz, 1H), 7.49 - 7.34 (m, 2H), 7.27 (d, J = 7.5 Hz, 2H), 6.52 (d, J = 8.8 Hz, 2H), 4.68 (d, J = 10.5 Hz, 2H), 3.84 (dd, J = 33.5, 3.9 Hz, 8H), 3.64 - 3.50 (m, 1H), 3.34 - 3.07 (m, 2H), 2.28 - 2.08 (m, 2H), 1.44 (dd, J = 21.4, 10.4 Hz, 2H). Mass: ESI [M+ 1] :585.
    • N-(3,4-dichlorophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine(compound compound 1B26, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 8.6 Hz, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.65 (d, J = 53.6 Hz, 1H), 7.48 - 7.35 (m, 2H), 7.20 (d, J = 8.7 Hz, 1H), 6.71 (d, J = 2.7 Hz, 1H), 6.46 (dd, J = 8.7, 2.7 Hz, 1H), 4.69 (d, J = 17.3 Hz, 2H), 3.84 (d, J = 36.2 Hz, 8H), 3.55 (ddd, J = 14.0, 9.9, 4.2 Hz, 1H), 3.21 (dd, J = 14.7, 9.4 Hz, 2H), 2.26 - 2.11 (m, 2H), 1.47 - 1.38 (m, 2H). Mass: ESI [M+ 1] :575.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-fluorophenyl)piperidin-4-amine(compound compound 1B27, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 7.5 Hz, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 53.6 Hz, 1H), 7.41 (ddd, J = 8.4, 7.1, 3.5 Hz, 2H), 7.06 - 6.94 (m, 2H), 6.77 (t, J = 7.9 Hz, 1H), 6.71 - 6.59 (m, 1H), 4.67 (d, J = 8.7 Hz, 2H), 3.84 (dd, J = 33.4, 4.4 Hz, 8H), 3.70 - 3.55 (m, 1H), 3.36 - 3.15 (m, 2H), 2.21 (t, J = 12.3 Hz, 2H), 1.50 (d, J = 10.5 Hz, 2H). Mass: ESI [M+ 1] :525.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-methoxyphenyl)piperidin-4-amine(compound compound 1B28, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 53.6 Hz, 1H), 7.47 - 7.35 (m, 2H), 6.89 (td, J = 7.8, 1.3 Hz, 1H), 6.79 (dd, J = 8.2, 1.1 Hz, 1H), 6.69 (dd, J = 10.1, 3.7 Hz, 2H), 4.63 (d, J = 7.6 Hz, 2H), 3.88 (d, J = 5.0 Hz, 4H), 3.84 (s, 3H), 3.80 (d, J = 4.5 Hz, 4H), 3.68 - 3.55 (m, 1H), 3.29 (dt, J = 23.5, 11.6 Hz, 2H), 2.30 - 2.09 (m, 2H), 1.58 - 1.44 (m, 2H). Mass: ESI [M + 1] :537.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)phenyl)piperidin-4-amine(compound compound 1B29, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J = 7.5 Hz, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 53.6 Hz, 1H), 7.41 (ddd, J = 8.4, 7.1, 3.5 Hz, 2H), 7.06 - 6.94 (m, 2H), 6.92 (t, J = 7.9 Hz, 1H), 6.71 - 6.59 (m, 1H), 4.67 (d, J = 8.7 Hz, 2H), 3.84 (dd, J = 33.4, 4.4 Hz, 8H), 3.70 - 3.55 (m, 1H), 3.36 - 3.15 (m, 2H), 2.21 (t, J = 12.3 Hz, 2H), 1.50 (d, J = 10.5 Hz, 2H). Mass: ESI [M+ 1] :575.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(p-tolyl)piperidin-4-amine(compound compound 1B30, Table 5, Fig 3)
  • 1H NMR (400 MHz, CDCl3) :: δ 8.34 (d, J = 7.4 Hz, 1H), 7.90 (d, J = 7.2 Hz, 1H), 7.65 (t, J = 53.7 Hz, 1H), 7.42 (m, 2H), 7.05 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 8.9 Hz, 2H), 4.69 (d, J = 17.1 Hz, 2H), 3.84 (dd, J = 34.0, 3.7 Hz, 8H), 3.58 (m, 1H), 3.35 - 3.09 (m, 2H), 2.58 (s, 3H), 2.30 - 2.11 (m, 2H), 1.45 (dd, J = 22.0, 9.8 Hz, 2H). Mass: ESI [M+ 1] : 522.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(3-methoxyphenyl)piperidin-4-amine(compound compound 1B31, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) :δ 8.34 (d, J = 7.4 Hz, 1H), 7.90 (d, J = 7.2 Hz, 1H), 7.65 (t, J = 53.7 Hz, 1H), 7.42 (m, 2H), 7.09 (s, 1H), 7.05 (d, J = 6.5 Hz, 1H), 6.75 (d, J = 8.9 Hz, 2H), 4.69 (d, J = 17.1 Hz, 2H), 3.84 (dd, J = 34.0, 3.7 Hz, 8H), 3.58 (m, 1H), 3.42 (s, 3H), 3.35 - 3.09 (m, 2H), 2.30 - 2.11 (m, 2H), 1.45 (dd, J = 22.0, 9.8 Hz, 2H).Mass: ESI [M + 1] : 537.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(o-tolyl)piperidin-4-amine(compound 1B32, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) : δ 8.34 (d, J = 7.4 Hz, 1H), 7.90 (d, J = 7.2 Hz, 1H), 7.65 (t, J = 53.7 Hz, 1H), 7.42 (m, 2H), 7.15 (d, J = 8.5 Hz, 1H), 7.05 (d, J = 6.5 Hz, 1H), 6.60 (d, J = 8.9 Hz, 2H), 4.69 (d, J = 17.1 Hz, 2H), 3.84 (dd, J = 34.0, 3.7 Hz, 8H), 3.58 (m, 1H), 3.35 - 3.09 (m, 2H), 2.43 (s, 3H), 2.30 - 2.11 (m, 2H), 1.45 (dd, J = 22.0, 9.8 Hz, 2H).Mass: ESI [M+ 1] : 521.
    • 1-(4-(5-fluoro-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(p-tolyl)piperidin-4-amine(compound 1B33, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.48 (s, 1H), 7.82 (dd, J = 7.5, 5.0 Hz, 1H), 7.49 (dd, J = 8.0, 1.5 Hz, 1H), 7.11 - 6.96 (m, 3H), 6.50 (d, J = 7.4 Hz, 2H), 3.80 (dd, J = 13.9, 9.2 Hz, 5H), 3.53 (dddd, J = 20.4, 14.8, 7.8, 3.9 Hz, 7H), 3.29 (dt, J = 12.3, 5.6 Hz, 2H), 2.30 (s, 3H), 1.92 (dtd, J = 12.2, 5.6, 3.1 Hz, 2H), 1.79 (dtd, J = 12.4, 5.6, 3.1 Hz, 2H) Mass: ESI [M+ 1] : 489.
    • 1-(4-(2-(difluoromethyl)-5-fluoro-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoromethyl)phenyl)piperidin-4-amine (compound 1B34, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.47 (s, 1H), 7.81 (dd, J = 7.5, 5.0 Hz, 1H), 7.53 - 7.39 (m, 3H), 7.07 (td, J = 7.8, 1.4 Hz, 1H), 6.63 (d, J = 7.4 Hz, 2H), 3.79 (t, J = 4.8 Hz, 4H), 3.63 - 3.41 (m, 7H), 3.13 (dt, J = 12.3, 5.6 Hz, 2H), 1.90 (dtd, J = 12.3, 5.6, 3.9 Hz, 2H), 1.78 (dtd, J = 12.4, 5.6, 3.9 Hz, 2H), 0.36 (s, 1H) Mass: ESI [M + 1] : 543.
    • 1-(4-(1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoromethyl)phenyl) piperidin-4-amine(compound 1B35, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.45 (s, 1H), 8.18 - 7.75 (m, 1H), 7.74 - 7.48 (m, 1H), 7.43 (d, J = 7.6 Hz, 2H), 7.30 (pd, J = 7.5, 1.7 Hz, 2H), 6.63 (d, J = 7.4 Hz, 2H), 3.79 (t, J = 4.8 Hz, 4H), 3.63 - 3.41 (m, 7H), 3.13 (dt, J = 12.4, 5.6 Hz, 2H), 1.90 (dtd, J = 12.3, 5.6, 3.9 Hz, 2H), 1.78 (dtd, J = 12.3, 5.6, 3.8 Hz, 2H), 0.37 (s, 1H) Mass: ESI [M + 1] : 525.
    • 1-(4-(1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoromethoxy)phe nyl)piperidin-4-amine (compound 1B36, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.18 (s, 1H), 8.15 - 7.72 (m, 1H), 7.68 - 7.52 (m, 1H), 7.29 (dtd, J = 19.6, 7.4, 1.7 Hz, 2H), 6.77 (d, J = 7.4 Hz, 2H), 6.50 (d, J = 7.4 Hz, 2H), 3.95 (s, 1H), 3.79 (t, J = 4.9 Hz, 4H), 3.61 - 3.42 (m, 7H), 3.29 (dt, J = 12.5, 6.3 Hz, 2H), 1.97 - 1.74 (m, 4H) Mass: ESI [M+ 1] : 541.
    • 1-(4-(1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)piperidin-4-amine(compound 1B37, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 8.14 - 7.73 (m, 1H), 7.68 - 7.52 (m, 1H), 7.29 (dtd, J = 19.5, 7.4, 1.6 Hz, 2H), 6.86 (t, J = 7.7 Hz, 2H), 6.58 - 6.46 (m, 2H), 3.78 (t, J = 4.9 Hz, 4H), 3.58 - 3.27 (m, 10H), 1.97 (ddt, J = 12.2, 7.4, 6.0 Hz, 2H), 1.81 (ddt, J = 12.3, 7.5, 6.1 Hz, 2H) Mass: ESI [ M + 1] : 475.
    • 1-(4-(1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-fluorophenyl)piperidin-4-amine(compound 1B38, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 8.15 - 7.71 (m, 1H), 7.68 - 7.52 (m, 1H), 7.29 (dtd, J = 19.5, 7.4, 1.6 Hz, 2H), 6.93 - 6.80 (m, 2H), 6.69 - 6.51 (m, 2H), 4.00 (s, 1H), 3.79 (t, J = 4.9Hz, 4H), 3.57 -3.38 (m, 7H), 3.36 - 3.25 (m, 2H), 2.06 - 1.93 (m, 2H), 1.91 - 1.79 (m, 2H) Mass: ESI [M+ 1] : 475.
    • 1-(4-(1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-chlorophenyl)piperidin-4-amine(compound 1B39, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.60 - 7.71 (m, 2H), 7.68 - 7.52 (m, 1H), 7.29 (dtd, J = 19.5, 7.4, 1.6 Hz, 2H), 7.14 (dd, J = 7.5, 1.4 Hz, 1H), 7.02 (td, J = 7.5, 1.4 Hz, 1H), 6.64 - 6.51 (m, 2H), 4.64 (s, 1H), 3.79 (t, J = 4.9 Hz, 4H), 3.57 - 3.41 (m, 7H), 3.36 - 3.25 (m, 2H), 2.06 - 1.93 (m, 2H), 1.91 - 1.78 (m, 2H) Mass: ESI [M + 1] : 491.
    • 1-(4-(1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)phenyl) piperidin-4-amine(compound 1B40, Table 6, Fig 3)
  • 1H NMR (400 MHz, CDCl3) δ 8.47 (s, 5H), 8.18 - 7.76 (m, 5H), 7.74 - 7.33 (m, 11H), 7.33 (d, J = 1.9 Hz, 1H), 7.36 - 7.23 (m, 10H), 7.18 (td, J = 7.5, 1.4 Hz, 5H), 6.65 (td, J = 7.5, 1.5 Hz, 5H), 6.56 (dd, J = 7.5, 1.5 Hz, 5H), 4.82 (s, 5H), 3.78 (t, J = 4.5 Hz, 20H), 3.59 - 3.29 (m, 45H), 2.11 - 1.98 (m, 10H), 1.77 - 1.63 (m, 10H) Mass: ESI [M+ 1] : 525.
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N,N-bis(4-fluorophenyl)piperidin-4-amine (compound 1B41, Table 7, Fig 4)
  • 1H NMR (400 MHz, CDCl3) δ 7.78 (dt, J = 14.5, 7.2 Hz, 1H), 7.59 (dd, J = 7.3, 1.8 Hz, 1H), 7.33 - 7.20 (m, 2H), 7.07 (d, J = 40.9 Hz, 1H), 7.05 - 6.87 (m, 8H), 4.02 (tt, J = 8.0, 5.0 Hz, 1H), 3.78 (t, J = 4.8 Hz, 4H), 3.54 (t, J = 4.9 Hz, 2H), 3.49 - 3.37 (m, 4H), 3.31 (dt, J = 12.4, 5.3 Hz, 2H), 2.26 - 2.15 (m, 2H), 1.88 - 1.75 (m, 2H).Mass: ESI [M+ 1] : 619
    • N-(4-bromophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-tluorophenyl)piperidin-4-amine (compound 1B42, Table 7, Fig 4)
  • 1H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 6.9, 2.1 Hz, 1H), 7.65 (dd, J = 6.9, 2.2 Hz, 1H), 7.34 (d, J = 7.6 Hz, 2H), 7.31 - 7.21 (m, 2H), 7.14 - 7.06 (m, 3H), 6.96 (t, J = 7.7 Hz, 2H), 6.84 (d, J = 7.4 Hz, 2H), 4.19 (p, J = 3.7 Hz, 1H), 3.79 (t, J = 4.8 Hz, 4H), 3.52 (ddt, J = 22.1, 9.5, 5.2 Hz, 6H), 3.21 - 3.07 (m, 2H), 2.09 (dtdd, J = 18.2, 12.3, 5.7, 3.7 Hz, 4H) Mass: ESI [M+ 1] : 679
    • 1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)-N-(4-(trifluoromethyl)phenyl)piperidin-4-amine (compound 1B43, Table 7, Fig 4)
  • 1H NMR (400 MHz, CDCl3) δ 7.85 - 7.74 (m, 1H), 7.70 - 7.58 (m, 1H), 7.48 (d, J = 7.6 Hz, 2H), 7.33 -7.21 (m, 2H), 7.12 (dd, J = 7.7, 4.1 Hz, 5H), 7.02 - 6.89 (m, 2H), 4.14 (p, J = 3.1 Hz, 1H), 3.78 (t, J = 4.5 Hz, 4H), 3.64 - 3.47 (m, 4H), 3.41 (t, J = 4.5 Hz, 2H), 3.25 (dt, J = 12.4, 5.3 Hz, 2H), 1.98 (dtd, J = 12.4, 5.3, 3.1 Hz, 2H), 1.83 (dtd, J = 12.4, 5.3, 3.1 Hz, 2H). ESI [M+ 1] : 669
    • N-(4-chlorophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)piperidin-4-amine (compound 1B44, Table 7, Fig 4)
  • 1H NMR (400 MHz, CDCl3) δ 7.76 (dd, J = 7.3, 1.6 Hz, 1H), 7.59 (dd, J = 7.3, 1.8 Hz, 1H), 7.26 (dqd, J = 14.5, 7.4, 1.6 Hz, 2H), 7.18 (d, J = 7.4 Hz, 2H), 7.12 (t, J = 12, 2H), 7.10 - 7.05 (m, 2H), 6.96 (t, J = 7.7 Hz, 2H), 6.88 (d, J = 7.6 Hz, 2H), 3.98 (tt, J = 8.1, 5.1 Hz, 1H), 3.78 (t, J = 4.9 Hz, 4H), 3.51 (t, J = 4.9 Hz, 2H), 3.47 - 3.39 (m, 4H), 3.30 (dt, J = 12.4, 5.4 Hz, 2H), 2.22 - 2.11 (m, 2H), 1.84 - 1.73 (m, 2H). ESI [M+ 1] : 635
    • N-(1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piper idin-4-yl)-N-(4-fluorophenyl)-3-(trifluoromethyl)pyridin-4-amine (compound 1B45, Table 7, Fig 4)
  • 1H NMR (400 MHz, CDCl3) δ 9.24 (s, 4H), 8.80 (d, J = 7.5 Hz, 4H), 7.89 - 7.77 (m, 4H), 7.65 (ddd, J = 20.2, 14.0, 6.4 Hz, 8H), 7.36 - 7.21 (m, 9H), 7.12 (s, 2H), 6.96 (ddd, J = 26.8, 11.5, 6.4 Hz, 17H), 4.41 (p, J = 7.5 Hz, 4H), 3.78 (t, J = 4.5 Hz, 14H), 3.62 (t, J = 4.5 Hz, 8H), 3.40 (tdt, J = 24.2, 12.2, 6.0 Hz, 24H), 2.22 (ddt, J = 12.2, 7.4, 6.0 Hz, 8H), 2.10 - 1.92 (m, 8H). ESI [M+ 1] : 670
    • 1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluoro phenyl)piperidin-4-amine (compound 1B46, Table 7, Fig 5)
  • 1H NMR (400 MHz, CDCl3) δ 7.49 - 7.40 (m, 1H), 7.33 - 7.24 (m, 1H), 7.23 - 7.13 (m, 2H), 7.07 (dd, J = 29.4, 28.0 Hz, 2H), 6.87 (t, J = 7.8 Hz, 2H), 6.57 - 6.47 (m, 2H), 4.25 (s, 1H), 3.78 (t, J = 4.5 Hz, 4H), 3.59 - 3.46 (m, 5H), 3.42 (t, J = 4.5 Hz, 2H), 3.19 (dt, J = 12.4, 5.4 Hz, 2H), 1.99 (dtd, J = 12.4, 5.4, 3.2 Hz, 2H), 1.71 (dtd, J = 12.4, 5.5, 3.2 Hz, 2H). ESI [M+ 1] :524
    • 1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-methoxy phenyl)piperidin-4-amine (compound 1B47, Table 7, Fig 5)
  • 1H NMR (400 MHz, CDCl3) δ 7.48 - 7.37 (m, 1H), 7.32 - 7.24 (m, 1H), 7.22 - 7.13 (m, 2H), 7.06 (dd, J = 29.4, 28.0 Hz, 2H), 6.75 (d, J = 7.4 Hz, 2H), 6.52 (d, J = 7.4 Hz, 2H), 3.79 (dd, J = 9.3, 4.8 Hz, 7H), 3.64 (s, 1H), 3.60 - 3.46 (m, 5H), 3.42 (t, J = 4.5 Hz, 2H), 3.25 (dt, J = 12.4, 5.5 Hz, 2H), 1.90 (dtd, J = 12.3, 5.4, 3.2 Hz, 2H), 1.71 (dtd, J = 12.4, 5.5, 3.2 Hz, 2H). ESI [M+ 1] : 536
    • 1-(4-(2-(ditluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B48, Table 7, Fig 5)
  • 1H NMR (400 MHz, CDCl3) δ 7.44 - 7.36 (m, 1H), 7.28 - 7.22 (m, 1H), 7.18 (ddd, J = 14.9, 7.2, 1.7 Hz, 2H), 7.13 - 6.96 (m, 2H), 6.76 (d, J = 7.4 Hz, 2H), 6.51 (d, J = 7.4 Hz, 2H), 3.79 (t, J = 4.9 Hz, 4H), 3.58 - 3.40 (m, 7H), 3.31 (p, J = 7.5 Hz, 1H), 3.20 (dt, J = 12.3, 5.5 Hz, 2H), 2.00 (ddt, J = 13.0, 7.6, 5.6 Hz, 2H), 1.81 (ddt, J = 13.0, 7.5, 5.5 Hz, 2H). ESI [M+ 1] : 590
    • 1-(4-(2-(ditluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B49, Table 7, Fig 5)
  • 1H NMR (400 MHz, CDCl3) δ 7.50 - 7.42 (m, 1H), 7.38 (d, J = 7.4 Hz, 2H), 7.27 - 7.13 (m, 3H), 7.07 (dd, J = 44.8, 14.7 Hz, 1H), 6.97 (d, J = 1.4 Hz, 1H), 6.52 (d, J = 7.4 Hz, 2H), 4.02 (s, 1H), 3.78 (t, J = 4.9 Hz, 4H), 3.61 (t, J = 4.9 Hz, 2H), 3.52 - 3.39 (m, 5H), 3.32 (dt, J = 12.3, 5.3 Hz, 2H), 2.03 - 1.92 (m, 2H), 1.86 - 1.75 (m, 2H). ESI [M + 1] : 574
    • N-(4-chlorophenyl)-1-(4-(2-(ditluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine (compound 1B50, Table 7, Fig 5)
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (dd, J = 7.1, 1.8 Hz, 1H), 7.30 - 7.25 (m, 1H), 7.18 (ddt, J = 7.8, 5.7, 1.6 Hz, 4H), 7.06 (dd, J = 29.4, 28.0 Hz, 2H), 6.49 (d, J = 7.4 Hz, 2H), 4.06 (s, 1H), 3.78 (t, J = 4.5 Hz, 4H), 3.59 - 3.46 (m, 5H), 3.42 (t, J = 4.5 Hz, 2H), 3.24 (dt, J = 12.4, 5.4 Hz, 2H), 1.89 (dtd, J = 12.4, 5.4, 3.2 Hz, 2H), 1.70 (dtd, J = 12.4, 5.4, 3.2 Hz, 2H). ESI [M + 1] : 540 Table 1
    Entry Code Structure Entry Code Structure
    1. 1A1
    Figure imgb0014
         		6. 1A6
    Figure imgb0015
    2. 1A2
    Figure imgb0016
         		7. 1A7
    Figure imgb0017
    3. 1A3
    Figure imgb0018
         		8. 1A8
    Figure imgb0019
    4. 1A4
    Figure imgb0020
         		9. 1A9
    Figure imgb0021
    5. 1A5
    Figure imgb0022
         		10. 1A10
    Figure imgb0023
    Table 2
    Entry Code Structure Entry Code Structure
    11 1A11
    Figure imgb0024
         		16 1A16
    Figure imgb0025
    12 1A12
    Figure imgb0026
         		17 1A17
    Figure imgb0027
    13 1A13
    Figure imgb0028
         		18 1A18
    Figure imgb0029
    14 1A14
    Figure imgb0030
         		19 1A19
    Figure imgb0031
    15 1A15
    Figure imgb0032
         		20 1A20
    Figure imgb0033
    Table 3
    Entry Code Structure Entry Code Structure
    21 1B1
    Figure imgb0034
         		26 1B6
    Figure imgb0035
    22 1B2
    Figure imgb0036
         		27 1B7
    Figure imgb0037
    23 1B3
    Figure imgb0038
         		28 1B8
    Figure imgb0039
    24 1B4
    Figure imgb0040
         		29 1B9
    Figure imgb0041
    25 1B5
    Figure imgb0042
         		30 1B10
    Figure imgb0043
    Table 4
    Entry Code Structure Entry Code Structure
    31 1B11
    Figure imgb0044
         		36 1B16
    Figure imgb0045
    32 1B12
    Figure imgb0046
         		37 1B17
    Figure imgb0047
    33 1B13
    Figure imgb0048
         		38 1B18
    Figure imgb0049
    34 1B14
    Figure imgb0050
         		39 1B19
    Figure imgb0051
    35 1B15
    Figure imgb0052
         		40 1B20
    Figure imgb0053
    Table 5
    Entry Code Structure Entry Code Structure
    41. 1B21
    Figure imgb0054
         		46. 1B26
    Figure imgb0055
    42. 1B22
    Figure imgb0056
         		47. 1B27
    Figure imgb0057
    43. 1B23
    Figure imgb0058
         		48. 1B28
    Figure imgb0059
    44. 1B24
    Figure imgb0060
         		49. 1B29
    Figure imgb0061
    45. 1B25
    Figure imgb0062
         		50. 1B30
    Figure imgb0063
    Table 6
    Entry Code Structure Entry Code Structure
    51 1B31
    Figure imgb0064
         		56 1B36
    Figure imgb0065
    52 1B32
    Figure imgb0066
         		57 1B37
    Figure imgb0067
    53 1B33
    Figure imgb0068
         		58 1B38
    Figure imgb0069
    54 1B34
    Figure imgb0070
         		59 1B39
    Figure imgb0071
    55 1B35
    Figure imgb0072
         		60 1B40
    Figure imgb0073
    Table 7
    Entry Code Structure Entry Code Structure
    61 1B41
    Figure imgb0074
         		66 1B46
    Figure imgb0075
    62 1B42
    Figure imgb0076
         		67 1B47
    Figure imgb0077
    63 1B43
    Figure imgb0078
         		68 1B48
    Figure imgb0079
    64 1B44
    Figure imgb0080
         		69 1B49
    Figure imgb0081
    65 1B45
    Figure imgb0082
         		70 1B50
    Figure imgb0083
    • Part B: Biological Evaluation Bio-chemical assay (PI3K inhibition assays).
  • Compounds were evaluated for their ability to inhibit class I PI3-kinase enzyme alpha as given below. PI3K-α assay: PI3K alpha (diluted in 12.5mM Glycine-NaOH (pH 8.5), 50 mM KCl, 2.5 mM MgCl2, 1 mM DTT, 0.05% CHAPS) is assayed in total volume of 20 ul containing 12.5 mM glycine-NaOH (pH 8.5), 50 mM KCl, 2.5 mM MgCl2, 1 mM DTT, 0.05% CHAPS, 0.01 mM ATP and 0.05 mM diC8 PIP2. The enzyme is assayed for 80 min after which 20 ul of ADP-Glo reagent is added. After a further incubation of 40 min, 40 ul of Kinase Detection Buffer is added. The assays are incubated for 40 min and then read on PerkinElmer Envision for 1sec/well.
  • Results: PI3K alpha % of inhibition values of a drug measures the effectiveness of a compound in inhibiting biological or biochemical function. The determination of enzyme based % of inhibition values helps in early analysis and estimation of the drug activities in order to narrow down drug candidates for further experimental purpose. The standard drug ZSTK474 shown greater than 70% inhibition at 500 nm against PI3K alpha and 30 compounds viz., 1A3, 1A5, 1A6, 1A8, 1A9, 1A10, 1A14, 1A15, 1A19, 1B1, 1B4, 1B8, 1B11, 1B12, 1B15, 1B18, 1B19, 1B23, 1B24, 1B25, 1B26, 1B28, 1B31, 1B34, 1B37, 1B41, 1B42, 1B43, 1B47 and 1B49 shown greater than 70% inhibition at 500nm against PI3K alpha. All the screening results given in Table 8.
    • In vitro cell line activity:
  • Cell culture, growth conditions and treatments: Human breast cancer cell lines MDAMB231, MFC-7 and human prostate carcinoma cell line PC-3 were obtained from European Collection of Cell Cultures (ECACC). Cells were grown in RPMI-1440 medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/ml), streptomycin (100 µg/ml), L-glutamine (0.3 mg/ml), sodium pyruvate (550 mg/ml), and NaHCO3(2mg/ml). Cells were grown in CO2 incubator (Thermocon Electron Corporation, USA) at 37°C in an atmosphere of 95% air and 5% CO2 with 98% humidity.
  • Different molecules were dissolved in DMSO and were delivered to cell cultures in complete medium.
  • Cell proliferation assay: MTT assay was done to determine the viability of the cells and was done as described previously (Kumar etal, 2013). Briefly, 6×103 were seeded in 96 well plates and were treated with different concentrations of different molecules for 5 days. 20 µl of MTT dye (2.5mg/ml) was added 3 h before the termination of the experiment. Formazen crystals were dissolved in 150 µl of DMSO and OD was measured at 570 nm.
  • Results: The several synthesized compounds were also checked for their antiproliferative activity against two breast cancer cell lines MDAMB231, MCF-7 and one prostate cancer cell line PC-3.
  • Many molecules displayed potent anti proliferative activities in in vitro cancer cell lines assay and all the results given in Table 9. Standard drug ZSTK474 were taken as reference standard Table 8
    Entry Code In vitro PI3K α % of inhibition * Entry Code In vitro PI3K α % of inhibition* Entry Code In vitro PI3K α % of inhibition*
    1. 1A1 + 25. 1B5 + 49. 1B29 +
    2. 1A2 + 26. 1B6 + 50. 1B30 +
    3. 1A3 ++ 27. 1B7 + 51. 1B31 ++
    4. 1A4 + 28. 1B8 ++ 52. 1B32 +
    5. 1A5 ++ 29. 1B9 + 53. 1B33 +
    6. 1A6 ++ 30. 1B10 + 54. 1B34 ++
    7. 1A7 + 31. 1B11 ++ 55. 1B35 +
    8. 1A8 ++ 32. 1B12 ++ 56. 1B36 +
    9. 1A9 ++ 33. 1B13 + 57. 1B37 ++
    10. 1A10 ++ 34. 1B14 + 58. 1B38 +
    11. 1A11 + 35. 1B15 ++ 59. 1B39 +
    12. 1A12 + 36. 1B16 + 60. 1B40 +
    13. 1A13 + 37. 1B17 + 61. 1B41 ++
    14. 1A14 ++ 38. 1B18 ++ 62. 1B42 ++
    15. 1A15 ++ 39. 1B19 ++ 63. 1B43 ++
    16. 1A16 + 40. 1B20 + 64. 1B44 +
    17. 1A17 + 41. 1B21 + 65. 1B45 +
    18. 1A18 + 42. 1B22 + 66. 1B46 +
    19. 1A19 ++ 43. 1B23 ++ 67. 1B47 ++
    20. 1A20 + 44. 1B24 ++ 68. 1B48 +
    21. 1B1 ++ 45. 1B25 ++ 69. 1B49 ++
    22. 1B2 + 46. 1B26 ++ 70. 1B50 +
    23. 1B3 + 47 1B27 + 71. ZSTK474 ++
    24. 1B4 ++ 48 1B28 ++
    *In vitro PI3K alpha kinase inhibition at 500 nm; + indicates greater than 50% to 70% of inhibition and
    ++ indicates greater than 70% of inhibition.
    Table 9
    Entry Code MCF-7 Cell line %inhibition at 10µM* PC-3 Cell line %inhibition at 10µM* MDA-MB231 Cell line %inhibition at 10µM*
    1. 1A5 + ++ +
    2. 1A9 ++ + ++
    3. 1B1 ++ ++ ++
    4. 1B2 ++ + ++
    5. 1B4 NC NC NC
    6. 1B5 ++ NC +
    7. 1B6 ++ + NC
    8. 1B7 ++ NC +
    9. 1B10 NC NC NC
    10. 1B11 NC ++ +
    11. 1B12 ++ + +
    12. 1B22 + + NC
    13. 1B23 + + NC
    14. 1B24 NC NC +
    15. 1B25 ++ + NC
    16. 1B26 ++ + ++
    17. 1B27 ++ + +
    18. 1B28 ++ + NC
    19. 1B30 ++ + +
    20. 1B32 ++ + +
    21. ZSTK474 ++ ++ ++
    *In vitro cell line inhibition at 10µM: + indicates less than 30 to 50% of inhibition and ++ indicates greater than 50% of inhibition.

Claims (3)

  1. A compound selected from the group consisting of:
    4-(4-(4-fluorophenoxy)piperidin-1-yl)-N-methyl-6-morpholino-N-phenyl-1,3,5-triazin-2-amine (compound 1A1),
    4-(4-(2-fluorophenoxy)piperidin-1-yl)-N-methyl-6-morpholino-N-phenyl-1,3,5-triazin-2-amine (compound 1A2),
    4-(4-(4-fluorophenoxy)piperidin-l-yl)-N-(4-fluorophenyl)-N-methyl-6-morpholino-1,3,5-triazin-2-amine (compound 1A3),
    2,2,2-trifluoro-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide (compound 1A4),
    2,2,2-trifluoro-N-(4-fluorophenyl)-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)acetamide (compound 1A5),
    2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)acetamide (compound 1A6),
    2,2,2-trifluoro-N-(4-morpholino-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide (compound 1A7),
    2,2,2-trifluoro-N-(4-morpholino-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide (compound 1A8),
    2,2,2-trifluoro-N-(4-morpholino-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide (compound 1A9),
    2,2,2-trifluoro-N-(4-morpholino-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)-N-phenylacetamide (compound 1A10),
    2,2,2-trifluoro-N-methyl-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)acetamide (compound 1A11),
    2,2,2-trifluoro-N-(4-morpholino-6-(4-phenoxypiperidin-1-yl)-1,3,5-triazin-2-yl)-N-(2,2,2-trifluoro acetyl)acetamide (compound 1A12),
    2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2,2,2-trifluoroacetyl)acetamide (compound 1A13),
    2,2,2-trifluoro-N-(4-(4-(2-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2,2,2-trifluoroacetyl)acetamide (compound 1A14),
    2,2,2-trifluoro-N-(4-(4-(4-fluorophenoxy)piperidin-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-methyl acetamide (compound 1A15),
    N,N-dimethyl-4-morpholino-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-amine (compound 1A16),
    4-(4-(4-fluorophenoxy)piperidin-1-yl)-N,N-dimethyl-6-morpholino-1,3,5-triazin-2-amine (compound 1A17),
    4-morpholino-6-(4-phenoxypiperidin-1-yl)-N,N-diphenyl-1,3,5-triazin-2-amine (compound 1A18),
    4-morpholino-N,N-diphenyl-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-amine (compound 1A19),
    4-mofpholino-N,N-diphenyl-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-amine (compound 1A20),
    4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(4-fluorophenoxy) piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B1),
    4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(4-methoxyphenoxy) piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B2),
    4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethoxy )phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B3),
    4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(2-(trifluoromethyl) phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B4),
    4-(4-(4-(4-chlorophenoxy)piperidin-1-yl)-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B5),
    4-(4-(4-(3-chlorophenoxy)piperidin-1-yl)-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B6),
    4-(4-(4-(2-chlorophenoxy)piperidin-1-yl)-6-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B7),
    4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(3-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B8),
    4-(4-(2-(difluoromethyl)-lH-benzo[d]imidazol-1-yl)-6-(4-(2-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B9),
    4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B10),
    4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(m-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B11),
    4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-(4-(o-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B12),
    4-(4-(5-fluoro-1H-benzo[d]imidazol-1-yl)-6-(4-(p-tolyloxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B13),
    4-(4-(5-fluoro-1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B14),
    4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B15),
    4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B16),
    4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(4-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B17),
    4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(2-fluorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B18),
    4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(2-chlorophenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B19),
    4-(4-(1H-benzo[d]imidazol-1-yl)-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)-1,3,5-triazin-2-yl)morpholine (compound 1B20),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluoro phenyl)piperidin-4-amine (compound 1B21),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B22),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B23),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-methoxy phenyl)piperidin-4-amine (compound 1B24),
    N-(4-bromophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine (compound 1B25),
    N-(3,4-dichlorophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine (compound 1B26),
    1-(4-(2-(difluoromethyl 1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-fluoro phenyl)piperidin-4-amine (compound 1B27),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-methoxy phenyl)piperidin-4-amine (compound 1B28),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B29),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(p-tolyl) piperidin-4-amine (compound 1B30),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(3-methoxy phenyl)piperidin-4-amine (compound 1B31),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(o-tolyl) piperidin-4-amine (compound 1B32),
    1-(4-(2-(difluoromethyl)-5-fluoro-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(p-tolyl)piperidin-4-amine (compound 1B33),
    1-(4-(2-(difluoromethyl)-5-fluoro-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoromethyl)phenyl)piperidin-4-amine (compound 1B34),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B35),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B36),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluoro phenyl)piperidin-4-amine (compound 1B37),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-fluoro phenyl)piperidin-4-amine (compound 1B38),
    N-(2-chlorophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine (compound 1B39),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(2-(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B40),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N,N-bis(4-fluorophenyl)piperidin-4-amine (compound 1B41),
    N-(4-bromophenyl)-1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)piperidin-4-amine (compound 1B42),
    1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)-N-(4-(trifluoromethyl)phenyl)piperidin-4-amine(compound 1B43),
    N-(4-chlorophenyl)-N-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluorophenyl)piperidin-4-amine (compound 1B44),
    N-(1-(4-(2-(difluoromethyl)-1H-benzo[d]imidazole-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-yl)-N-(4-fluorophenyl)-3-(trifluoromethyl)pyridin-4-amine (compound 1B45),
    1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-fluoro phenyl)piperidin-4-amine (compound 1B46),
    1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-methoxy phenyl)piperidin-4-amine (compound 1B47),
    1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-(trifluoro methoxy)phenyl)piperidin-4-amine (compound 1B48),
    1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)-N-(4-10(trifluoro methyl)phenyl)piperidin-4-amine (compound 1B49), and
    N-(4-chlorophenyl)-1-(4-(2-(difluoromethyl)-1H-indol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperidin-4-amine (compound 1B50).
  2. Compound of claim 1 for use in the treatment or prevention of cancer.
  3. A process for the preparation of a compound of claim 1, wherein:
    (a) a disubstituted triazine compound of formula 5 is reacted with an aryloxy piperidine of formula 6
    Figure imgb0084
     in DMF in the presence of K2CO3, at room temperature for 24 hours to obtain a compound selected from compounds 1A1 to 1A20, wherein:
    G1 is Ph, G2 is CH3 and FG3 is 4-F or 2-F,
    G1 is (4-F)-Ph, G2 is CH3 and FG3 is 4-F,
    G1 is Ph, G2 is COCF3 and FG3 is selected from the group consisting of H, 4-CF3, 4-CH3, 4-OCF3, and 2-OCF3,
    G1 is (4-F)-Ph, G2 is COCF3 and FG3 is H or 4-F,
    G1 is CH3, G2 is COCF3 and FG3 is H or 4-F,
    G1 is COCF3, G2 is COCF3 and FG3 is selected from the group consisting of H, 4-F, and 2-F,
    G1 is CH3, G2 is CH3 and FG3 is H or 4-F, or
    G1 is Ph, G2 is Ph and FG3 is selected from the group consisting of H, 4-CF3 and 4-OCF3, or
    (b) a disubstituted triazine compound of formula 8 is reacted with an aryloxy piperidine of formula 6
    Figure imgb0085
     in DMF in the presence of K2CO3, at room temperature for 24 hours to obtain a compound selected from compounds 1B1 to 1B20, wherein:
    FG1 is H, FG2 is 2-CHF2 and FG3 is selected from the group consisting of 4-F, 4-OMe, 4-OCF3, 2-CF3, 4-Cl, 3-Cl, 2-Cl; 4-CN, 2-CN, 4-CH3, 3-CH3, and 2-CH3,
    FG1 is 5-F, FG2 is H and FG3 is 4-CH3 or 4-CF3, or
    FG1 is H, FG2 is H and FG3 is selected from the group consisting of 4-CF3, 4-OCF3, 4-F, 2-F, 4-Cl, and 2-CF3, or
    (c) a trisubstituted triazine compound of formula 10 is reacted with a substituted aryl amine of formula 11
    Figure imgb0086
     in DCM in the presence of acetic acid and sodium triacetoxy borohydride at room temperature for 24 hours to obtain a compound selected from compounds 1B21 to 1B40, wherein:
    FG1 is H, FG2 is 2-CHF2 and FG4 is selected from the group consisting of 4-F, 4-CF3, 4-OCF3, 4-OCH3, 4-Br, 3,4-di-Cl, 2-F, 2-OCH3, 2-CF3, 4-CH3, 3-OCH3, 2-CH3,
    FG1 is 5-F, FG2 is H and FG4 is 4-CH3 or 4-CF3, or
    FG1 is H, FG2 is H and FG4 is selected from the group consisting of 4-CF3, 4-OCF3, 4-F, 2-F, 4-Cl, and 2-CF3,
    (d) a trisubstituted triazine compound of formula 1B21 is reacted with a substituted aryl boronic acid of formula 12
    Figure imgb0087
     in DCM in the presence of triethylamine and copper acetate at room temperature for 24 hours to obtain a compound selected from compounds 1B41 to 1B45, wherein:
    Y is CH and FG5 is selected from the group consisting of 4-F, 4-Br, 4-CF3, and 4-Cl, or
    Y is N and FG5 is 2-CF3, or
    (e) a trisubstituted triazine compound of formula 15 is reacted with a substituted aryl amine of formula 11
    Figure imgb0088
     in DCM in the presence of acetic acid and sodium triacetoxy borohydride at room temperature for 24 hours to obtain a compound selected from compounds 1B46 to 1B50, wherein:
    FG1 is H, FG2 is 2-CHF2 and FG4 is selected from the group consisting of 4-F, 4-OMe, 4-OCF3, 4-CF3 and 4-Cl.
EP15820891.8A 2014-11-20 2015-11-17 Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof Active EP3221307B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3369DE2014 2014-11-20
PCT/IN2015/050169 WO2016079760A1 (en) 2014-11-20 2015-11-17 Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof

Publications (2)

Publication Number Publication Date
EP3221307A1 EP3221307A1 (en) 2017-09-27
EP3221307B1 true EP3221307B1 (en) 2019-07-24

Family

ID=55073074

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15820891.8A Active EP3221307B1 (en) 2014-11-20 2015-11-17 Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof

Country Status (5)

Country Link
US (1) US9951040B2 (en)
EP (1) EP3221307B1 (en)
JP (1) JP6695875B2 (en)
CN (1) CN107428730B (en)
WO (1) WO2016079760A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022013684A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN113200969B (en) * 2021-05-19 2022-11-25 中国药科大学 PI3K alpha selective inhibitor and preparation method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137382B (en) * 2005-03-11 2012-11-21 全药工业株式会社 Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2010503649A (en) * 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ Pyrimidine derivatives
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
AU2009248993C1 (en) 2008-05-23 2013-10-03 Wyeth Llc Triazine compounds as PI3 kinase and mTOR inhibitors
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
AU2010229468A1 (en) * 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
GB201007227D0 (en) 2010-04-30 2010-06-16 Univ Basel Piperazinotriazines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
CN107428730B (en) 2020-10-16
WO2016079760A4 (en) 2016-07-28
JP2017535562A (en) 2017-11-30
CN107428730A (en) 2017-12-01
US20170342049A1 (en) 2017-11-30
US9951040B2 (en) 2018-04-24
EP3221307A1 (en) 2017-09-27
JP6695875B2 (en) 2020-05-20
WO2016079760A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
EP3080125B1 (en) Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same
JP7240784B2 (en) 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-ketone compounds
EP1539759B1 (en) Novel imidazopyridines and their use
RU2664055C2 (en) Dihydronaphthyridines and related compounds suitable as kinase inhibitors for treatment of proliferative diseases
CA3121667A1 (en) Isoindoline compound, preparation method, pharmaceutical composition and use thereof
JP6704422B2 (en) Quinazoline derivative salt and method for producing the same
JP2019503395A (en) Pyrrolopyrimidine 5-membered azacyclic derivatives and uses thereof
PT1294715E (en) Quinazoline ditosylate salt compounds
HUE034807T2 (en) Novel quinoline-substituted compound
EP3253754B1 (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
BR112015019790B1 (en) monocyclic pyridine derivative with fgfr inhibitory action or a pharmaceutically acceptable salt thereof for medical use
EP3166945B1 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
JP2020529968A (en) Substituted 5- and 6-membered heterocyclic compounds, their preparation methods, drug combinations and their use
WO2023147063A2 (en) Compounds and methods for yap/tead modulation and indications therefor
WO2022105526A1 (en) Dihydroisoquinolinone and isoindolinone derivatives and uses thereof
US9951040B2 (en) 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof
CN119585256A (en) Chemokine receptor modulators and uses thereof
CN110300587B (en) Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
EP3484867B1 (en) Inhibitors of tryptophan 2,3-dioxygenase
WO2024159079A1 (en) Compounds and methods for yap/tead modulation and indications therefor
EP3632912B1 (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
CN114026097B (en) Substituted pyrazoquinazolinone compounds and their applications
EP4384518B1 (en) Tyrosine kinase inhibitors
EP3632913A1 (en) Carboxylic acid derivatives of pyridoquinazolines useful as protein kinase inhibitors
WO2024159103A1 (en) Compounds and methods for yap/tead modulation and indications therefor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170519

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180508

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

INTG Intention to grant announced

Effective date: 20190225

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015034479

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1158013

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190724

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1158013

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191125

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191024

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191024

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191124

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191025

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015034479

Country of ref document: DE

Ref country code: DE

Ref legal event code: R119

Ref document number: 602015034479

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191117

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

26N No opposition filed

Effective date: 20200603

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191117

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20151117

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190724

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251118

Year of fee payment: 11